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ABSTRACT
ELUCIDATION OF SUBSTRATE BINDING INTERACTIONS FOR HUMAN ORGANIC
CATION TRANSPORTERS 1 (SLC22A1) AND 2 (SLC22A2) USING IN SILICO
HOMOLOGY MODELING IN CONJUNCTION WITH IN VITRO SITE-DIRECTED
MUTAGENESIS AND KINETIC ANALYSIS
Raymond Eugene Lai
Bachelor of Science, College of William and Mary, Williamsburg, Virginia, USA
Master of Science, Virginia Commonwealth University, Richmond, Virginia, USA
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of Philosophy at Virginia Commonwealth University
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Professor, Chair
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The organic cation transporters (OCTs) play a critical role in the absorption,
distribution and elimination of many drugs, hormones, herbal medicines, and
environmental toxins. Given the broad substrate specificity of OCTs, they fall victim to the
high susceptibility for contributing to harmful drug-drug interactions. Further defining how
human (h)OCTs mechanistically bind to its broad array of substrates will provide
significant insight to the understanding and prediction of drug-drug interactions in
polypharmacy patients and the advancement of future rational drug design for
xiv

therapeutics targeting OCTs. The goal of the current study was to elucidate the critical
amino acid residues for transporter-substrate binding interactions on human (h)OCT1 and
2 utilizing in silico molecular modeling techniques (homology modeling and automated
docking), as well as in vitro mutagenesis and kinetic transport experiments.
Three-dimensional homology models were generated for hOCT1 and 2 using
Piriformospora indica phosphate transporter (PiPT) serving as template. A putative
binding pocket was identified and used to dock the prototypical substrate MPP +. Docking
studies revealed five residues for each transporter (hOCT1 and hOCT2) that may be
critical for substrate-transporter interactions. The in silico data was used to guide
subsequent in vitro site-directed mutagenesis and kinetic analysis. Four hOCT1 mutants
(Gln241Lys, Thr245Lys, Tyr361Ala, and Glu447Lys) and three hOCT2 mutants
(Gln242Lys, Tyr362Phe, and Tyr362Ala) showed complete loss of MPP + transporter
activity. Decreased affinity for MPP+ was observed for Phe244Ser and Thr245Ser in
hOCT1, and Tyr245Ala in hOCT2. All amino acid residues highlighted in the in vitro
experiments may be potentially critical for substrate-transporter interactions particularly
Tyr361, Phe244 and Thr245 in hOCT1; and Tyr362 and Tyr245 in hOCT2. Docking of
known structurally divergent hOCT1 and hOCT2 substrates revealed similar binding
interactions as that identified for MPP +, albeit with some unique residues, suggesting the
presence of a large central cavity within both transporters.
Through the combination of in silico and in vitro experiments, a putative binding
pocket was defined and several residues important for substrate-transporter interaction
were identified and verified for hOCT1 and hOCT2. Further defining how OCTs
biochemically interact with their broad array of substrates will provide significant insight

xv

to the understanding and prediction of drug-drug interactions in polypharmacy patients
and the advancement of future rational drug design for therapeutics targeting OCT1 and
OCT2.
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CHAPTER 1

OVERVIEW OF EXPRESSION AND FUNCTION OF ORGANIC CATION AND ANION
TRANSPORTERS

Adapted from manuscript published in Journal of Food and Drug Analysis. (2018) 2:
S45-S60 [1]

1.A

SOLUTE CARRIER 22 TRANSPORTER FAMILY
Almost a quarter century has passed since the cloning of the first member of what

is now recognized as the Solute Carrier 22 (SLC22) organic cation/anion/zwitterion
transporter family. Currently, the Human Genome Organization Gene Nomenclature
Committee

recognizes

some

50

SLC

families

(http://www.genenames.org/cgi-

bin/genefamilies/set/752) with the SLC22 family containing 23 proposed members. The
SLC22 family includes the organic anion transporters (OATs), organic cation transporters
(OCTs) and organic cation/carnitine transporters (OCTNs) [2]. Eight members are
extensively understood in terms of transport function, substrate specificity and driving
forces; OCT1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3), OAT1 (SLC22A6), OAT2
(SLC22A7), OAT3 (SLC22A8), OAT4 (SLC22A11) and urate transporter 1 (URAT1,
SLC22A12). While SLC22 family members are expressed in virtually every barrier
membrane within the human body (including the blood-testis barrier, blood-brain barrier,
blood-cerebrospinal fluid barrier, and various CNS cell types), expression and function in
kidney, liver and intestine has received the most attention (Figure 1.1).

1

Structurally, members of the SLC22 family are proposed to have 12 membranespanning alpha helical domains, a large extracellular glycosylated loop between
transmembrane domains (TMD) 1 and 2, a large intracellular loop between TMDs 6 and
7, and intracellular N and C-terminal domains [3] (predicted secondary structure of SLC22
family transporters shown in Figure 1.2). Within the large loop between the first and
second TMDs, three N-linked glycosylation sites are present which are proposed to serve
a variety of functions including protein stabilization, intracellular trafficking, and
extracellular protease protection [4]. Six sulfhydryl groups (conserved cysteine residues)
are also present which are theorized as mediators for forming ionic salt bridges which
help stabilize the three dimensional loop structure critical for transporter oligomerization
[3–5]. SLC22 family transporters are known to be polyspecific, in other words, they have
the ability to translocate a variety of structurally diverse small molecules and can be
inhibited by numerous other compounds [6–9]. Transporters within a given subtype
commonly share a similar group of preferred substrates and inhibitors, as well as their
mechanism of transport.
OCT and OAT substrates cover a wide array of chemical structures and classes
including pharmacological agents (e.g., morphine, tamoxifen, metformin, cimetidine,
penicillin G, furosemide, adefovir, cidofovir, indomethacin), neurotransmitters and their
metabolites

(e.g.,

dopamine,

serotonin,

homovanillic

acid),

hormones

(e.g.,

prostaglandins, estrone sulfate), environmental toxins/pollutants (e.g., paraquat, 1methyl-4-phenylpyridinium, ochratoxin A) and active components found in herbal
preparations (e.g., lithospermic acid, rosmarinic acid, rhein).

2

Experiments with renal membrane vesicles, tissue slices and intact tubules
demonstrated that the inside negative membrane potential of a cell drives the uptake
(cellular entry) of organic cations [10]. That is, cellular entry of organic cations mediated
by SLC22 family members involves facilitated diffusion, which is ‘powered’ by the
membrane potential difference and chemical gradient (Figure 1.3). The driving force for
cellular exit mediated by this transport system was found to be a three-step process
ending in organic cation/proton (H+) exchange [10]. Initially, Na+/K+-ATPase directly
hydrolyzes ATP and pumps Na+ out of the cell to establish an inwardly directed Na+
gradient, which is subsequently used by Na+/H+ exchanger 3 to establish an inwardly
directed H+ gradient, that ultimately serves to power cellular exit of organic cations via an
organic cation/H+ antiporter (Figure 1.3).

3

Figure 1.1 Prominent human SLC22 family members expressed in intestine, kidney
and liver.
Representative depictions of a human enterocyte, hepatocyte and renal proximal tubular
cell indicating SLC22 transporters expressed in each tissue and their plasma membrane
localization.
Figure taken from reference [1].
4

Figure 1.2 Predicted secondary structure of SLC22 transporters.

5

Figure 1.3 Model depicting driving forces for SLC22 family members.
Mechanisms/driving forces utilized for cellular entry and exit on the ‘classical’ organic
cation and organic anion transport systems, using renal proximal tubule cell as an
example.
Figure taken from reference [1].
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For organic anions, cellular entry mediated by SLC22 family members requires
energy input to drive their movement against the membrane potential (Figure 2).
Experiments utilizing the above-mentioned systems demonstrated that uptake was
coupled to established ion gradients (e.g., Na+, α-ketoglutarate) and not to direct ATP
hydrolysis [10]. That is, cellular entry of organic anions mediated by SLC22 family
members is driven by a three step process (similar to exit of organic cations) in which
Na+/K+-ATPase establishes the inwardly directed Na+ gradient, the Na+/dicarboxylate
symporter 3 utilizes the movement of Na+ ions down their concentration gradient (into the
cell) to power entry of α–ketoglutarate into the cell (maintaining an outwardly directed
gradient) and, finally, an organic anion/dicarboxylate antiporter mediates organic anion
uptake in exchange for α–ketoglutarate [10]. Evidence supports cellular exit via this
transport system occurring either by facilitated diffusion (using the membrane potential
as driving force) or anion exchange (antiport) [10].
A brief synopsis of the discovery of the well-characterized family members is
presented below, for additional detail see [11–14]. For the purposes of this dissertation,
subsequent discussion and experimental focus will be on human OCT1, OCT2, and
OCT3.

7

1.B

MAJOR ORGANIC CATION AND ANION TRANSPORTERS
OCT1 (SLC22A1). First isolated from rat kidney in 1994, orthologs have been

identified in mouse and human (as well as other species) [15–17]. In humans, OCT1
expression has been conclusively reported in enterocytes and hepatocytes [15,18]. Rat
Oct1 transport function correlated with changes in membrane potential, but not proton
gradient manipulations, indicating OCT1 is driven by facilitated diffusion [17]. Protein
expression in rats was subsequently confirmed by immunocytochemistry in renal proximal
tubules and hepatocytes [19,20].
OCT2 (SLC22A2). Isolated in 1996 from rat kidney, orthologs have been identified
in mouse and human (as well as other species) [15,21,22]. In humans, significant OCT2
expression has been reported in kidney, as well as in the CNS compartment [15,23–25].
Rat Oct2 transport function was ablated by membrane depolarization or a trans-applied
proton gradient, indicating it is also driven by facilitated diffusion [26]. Renal expression
and basolateral membrane targeting in intact rat proximal tubules was observed [27,28].
OCT3 (SLC22A3). Initially cloned from rat placenta [29], mouse and human
orthologs (as well as other species) have been identified [30,31]. OCT3 appears to have
the widest tissue distribution among the SLC22 family, including liver, kidney and intestine
in humans [24,29,30]. Rat Oct3 function was demonstrated to be sensitive to changes in
membrane potential indicating that it also is a facilitated diffusion carrier [29].
OAT1 (SLC22A6). Isolated in 1997 from rat kidney [32,33], orthologs have been
identified in mouse and human (as well as additional species) [34–36]. OAT1 is expressed
in kidney of all three species, but not in intestine or liver [25,33–35]. Renal expression
and basolateral membrane targeting in isolated proximal tubules and human and rat
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kidney was observed [37–39]. Mechanistic examination of rat Oct1 transport function
demonstrated it is an organic anion/dicarboxylate exchanger [33].
OAT2 (SLC22A7). OAT2 was initially cloned from rat liver [40] and human and
murine orthologs have been isolated [41,42]. Expression of OAT2 in kidney and liver, but
not intestine, has been detected in mouse, rat and human [43,58,60,61]. OAT2-mediated
uptake was characterized as being insensitive to trans-stimulation by dicarboxylates
leading to the interpretation it likely operates via facilitated diffusion [45]. However,
mechanistically, this would be inconsistent with its postulated role as an uptake carrier.
OAT3 (SLC22A8). OAT3 was first isolated from rat [46] with mouse and human
(as well as other species) orthologs identified [47,48]. OAT3 expression has been
observed in human kidney, but not liver or intestine [47]. Hepatic expression was reported
in rats, but not mice [44,48]. Immunohistochemistry yielded signal for OAT3 in rat and
human renal proximal tubules [37,38]. Exploration of OAT3 transport energetics identified
Na+-dependent trans-stimulation by glutarate indicating that it is driven by organic
anion/dicarboxylate exchange [49].
OAT4 (SLC22A11). OAT4 was discovered in human kidney and placenta [25,50].
No additional orthologs or tissues of expression have been identified. Immunodetection
in proximal tubules has been observed [51]. However, OAT4’s precise mechanism of
action remains unclear as it has been reported to be a facilitated-diffusion carrier [50], an
organic anion/dicarboxylate exchanger [52], and a urate/OH - exchanger [53].
URAT1 (SLC22A12). Originally isolated from mouse kidney, with rat and human
orthologs subsequently identified [54–56]. Expression of URAT1 appears to be kidney
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specific [55,56]. Characterization of URAT1-mediated transport indicated it functions as
an organic anion/urate exchanger, however, tested dicarboxylates failed to inhibit [55,56].
Three key factors needed to most accurately define each individual SLC22
transporter’s contribution to the transepithelial flux of substrate molecules in each tissue
are (i) individual transporter affinities for each compound, i.e., Km, Ki, IC50, (ii) the
concentration of each compound in the systemic circulation, and (iii) absolute SLC22
protein expression levels in each tissue, ideally in both normal and disease states. Robust
affinity data are relatively easy to come by using in vitro expression systems of which a
great deal already exists (Table 1.1). Limited clinical systemic concentration information
is available in the literature (Table 1.2), however, interpretation of these data should be
approached with caution at this time due to the use of non-standardized dosage forms
and inconsistent amounts of individual compounds administered in each study. Thus,
more formalized clinical studies that administer actual marketed products are required to
obtain relevant, product-specific (unbound) Cmax values for each compound. Within this
framework, organ-specific SLC22 protein expression data will further enhance our ability
to accurately predict their impact on the absorption/flux of drugs, herbal supplement
components and endogenous compounds. Toward this end, advances in liquid
chromatography/tandem mass spectrometry methodology have begun to yield
preliminary data regarding ‘normal’ human transporter expression levels in native cell
membranes (summarized for SLC22 transporters in Table 1.3).
Future studies quantifying transporter expression levels in patients suffering from
acute and chronic disease appear essential (e.g. renal or hepatic failure), as recent
studies using rat models of ischemia/reperfusion injury and chronic renal failure have
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demonstrated dramatic changes in SLC22 transporter expression levels. A common
theme to all of these studies was a significant (~50-85%) downregulation of Oat1 and
Oat3, and in one instance Oct2, protein expression in rat kidney as determined by
immunoblotting [57–62]. When examined, this downregulation of SLC22 expression
correlated with decreased renal clearance of Oat1 and Oat3 substrates [57,58,61]. For
example, in the ischemia/reperfusion model, significant accumulation of endogenous
indoxyl sulfate in the systemic circulation was observed beginning at 6 hours post injury
and the concentration of administered famotidine (20 mg/kg), a substrate for both OCTs
and OATs, was significantly elevated compared to control rats [58,59]. Thus, quantifying
transporter protein levels under conditions of organ dysfunction/insufficiency should
substantially improve modeling and prediction of compound distribution in such patients.
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Table 1.1 Example compound interactions associated with SLC22 transporters.
Kinetics (µM)
Perpetrator
Aloe-emodin
Chrysophanol

Victim
substrateb
6-CF
6-CF
6-CF
6-CF

Cisplatin
CMPFa
Diclofenac
Diflunisal
Emodin
Ethambutol

Etodolac
Flurbiprofen
Gallic acid
Ibuprofen
Indomethacin
Indoxyl sulfate
Ketoprofen
Lithospermic acid

Adefovir
Adefovir
6-CF
6-CF
MPP+
MPP+
MPP+
Adefovir
Adefovir
PAH
ES
Adefovir
Adefovir

Adefovir
PAH
ES

Transporterc

Cell Typed

hOAT1
hOAT3
hOAT1
hOAT3
hOCT2
hOAT1
hOAT3
hOAT1
hOAT1
hOAT1
hOAT3
hOCT1
hOCT2
hOCT3
hOAT1
hOAT1
hOAT1
hOAT3
hOAT1
hOAT1
hOAT1
hOAT3
hOAT1
hOAT1
hOAT3

MDCK
HEK293
MDCK
HEK293
HEK293
HEK293
HEK293
CHO
CHO
MDCK
HEK293
HEK293
HEK293
HEK293
CHO
CHO
CHO
HEK293
CHO
CHO
HEK293
HEK293
CHO
CHO
HEK293
12

Km

IC50

Ki

2.29
5.37
>10
>10
11
141
27
4
0.85
0.61
1.22
93
254
4100
50
1.5
1.2
9
8
3

1.1
8.4

21
263
1.3
20.8
0.59

Reference
[63]
[63]
[63]
[63]
[64]
[65]
[65]
[66]
[66]
[63]
[63]
[67]
[67]
[67]
[66]
[66]
[68]
[68]
[66]
[66]
[65]
[65]
[66]
[69]
[69]

PAH
ES
Nadolol
Naproxen
p-cresyl sulfate
Phenacetin
Physcion
Piroxicam
Rhein

Rosmarinic acid

Rosuvastatin
Salvianolic acid A

Adefovir
6-CF
6-CF
Adefovir
6-CF
6-CF

mOat1
mOat3
hOCT2
hOAT1
hOAT1
hOAT3
hOAT1
hOAT1
hOAT3
hOAT1
hOAT1
hOAT3

CHO
CHO
HEK293
CHO
HEK293
HEK293
CHO
MDCK
HEK293
CHO
MDCK
HEK293

PAH

hOAT1

CHO

ES
ES

hOAT3
hOAT4

CHO
CHO

PAH

mOat1

CHO

ES
PAH
ES
PAH
ES
ES
PAH
ES
PAH
ES

mOat3
hOAT1
hOAT3
mOat1
mOat3
hOAT3
hOAT1
hOAT3
mOat1
mOat3

CHO
CHO
HEK293
CHO
CHO
Xenopus oocytes
CHO
HEK293
CHO
CHO

Adefovir
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14.9
31.1
122
5.8
128
>5000
200
> 10
> 10
20.5
0.23
0.08
0.077
0.008
>100

7.4

0.07
2
0.00
8
>100
0.19
8
0.21
6
0.35
0.55
5.5
4.3

25.7
5.6
0.16
4.9
21.3

[69]
[69]
[70]
[66]
[71]
[71]
[66]
[63]
[63]
[66]
[63]
[63]
[72]
[72]
[72]
[72]
[72]
[69]
[69]
[69]
[69]
[73]
[69]
[69]
[69]
[69]

Salvianolic acid B

Tanshinol

Ursolic Acid

PAH
ES
PAH
ES
PAH
ES
PAH
ES
ES

hOAT1
hOAT3
mOat1
mOat3
hOAT1
hOAT3
mOat1
mOat3
hOAT3

CHO
HEK293
CHO
CHO
CHO
HEK293
CHO
CHO
HEK293

a CMPF,

22.2
19.8
236
845
40.4
8.6
136
1940
19

3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid
b 6-CF, 6-Carboxyfluorescein; PAH, p-aminohippurate; ES, estrone sulfate
c h, human; m, murine
d MDCK, Madin-Darby canine kidney; HEK293, human embryonic kidney; CHO, Chinese hamster ovary
Table taken from reference [1]

14

[69]
[69]
[69]
[69]
[69]
[69]
[69]
[69]
[74]

Table 1.2 Clinical concentrations of example compounds.
Mean
Route of
Compound
Dose
Cmax (µM)a
Administration
Aloe-emodin
0.29
PO
1.25 mg/kgb
Cisplatin
0.02-0.03
IV
80 mg/m2
Chrysophanol
4.7
PO
1.25 mg/kgb
CMPFc
24.8
Diclofenac
6.6
PO
100 mg
Diflunisal
247.8
PO
500 mg
Emodin
0.14
PO
1.25 mg/kgb
Ethambutol
22, 4.8-26.9
PO
25 mg/kg, 400 mg
Etodolac
26.1-57.1
PO
50 mg/kg
Flurbiprofen
172.3
PO
100 mg
Gallic acid
0.55
PO
400 mg/kg (40 µg)d
Ibuprofen
208.4-282.1
PO
800 mg
Indomethicin
3.9-6.7
PO
40 mg, 50 mg
Indoxyl Sulfate
2.5
Ketoprofen
13.8-17.8
PO
100 mg
Lithospermic Acid
55.7
IV
10 mL/kg (0.3 mg/kg)e
Nadolol
0.17
PO
30 mg
Naproxen
187.1
PO
220 mg
p-cresyl sulfate
425.1
Phenacetin
12.5
PO
900 mg
Physcion
1.7
PO
1.25 mg/kgb
Piroxicam
1.3
PO
20 mg
Rhein
0.54, 2.6
PO
1.25 mg/kgc, 6 g/kgf
Rosmarinic acid
317.2
PO
20 g/kg (0.391 mg/g)g
15

Species

Reference

Rat
Human
Rat
Human
Human
Human
Rat
Human
Rat
Human
Human
Human
Human
Human
Human
Rat
Human
Human
Human
Human
Rat
Human
Rat
Rat

[75]
[76]
[75]
[77]
[78]
[79]
[75]
[80], [81]
[82]
[83]
[84]
[85]
[86]
[87]
[88]
[89]
[90]
[91]
[87]
[92]
[75]
[93]
[75], [94]
[95]

516.2
IV
10 mL/kg (1.86 mg/kg)e
Rat
[89]
Rosuvastatin
0.012-0.076
PO
20 mg
Human
[96]
h
Salvianolic acid A
0.28
PO
15 g/kg (37.9 mg/kg)
Rat
[97]
e
66.7
IV
10 mL/kg (0.33 mg/kg)
Rat
[89]
h
Salvianolic acid B
0.14
PO
15 g/kg (15 mg/kg)
Rat
[97]
e
237.9
IV
10 mL/kg (1.714 mg/kg)
Rat
[89]
g
Tanshinol
781.7
PO
20 g/kg (0.743 mg/g)
Rat
[95]
i
Ursolic acid
2
PO
0.1 g/kg
Rat
[98]
a Converted to µM from original study
b Semen Cassiae extract
c CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid
d Mang-Guo-Zhi-Ke tablet, value in parenthesis represents amount of compound quantified in dosage form
e Danshen injection, value in parenthesis represents amount of compound quantified in dosage form
f Rhubarb extract
g Denshen-Chuanxiong-Honghua extract; value in parenthesis represents amount of compound quantified in dosage form
h Jitai tablet; value in parenthesis represents amount of compound quantified in dosage form
i Folium Eriobotryae effective fraction
Table taken from reference [1]
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Table 1.3 Absolute native tissue protein expression levels for human SLC22 transporters.
Kidneya

Livera

Intestinea

Reference

OAT1

5.33±1.88

NEb

NEb

[25]

OAT2

0.93±0.32

1.91±0.58

NEb

[25], [99]

OAT3

3.50±1.55

NEb

NEb

[25]

OAT4

0.52±0.23

NEb

NEb

[25]

OCT1

NEb

7.35 ± 3.26, 4.45 ± 1.89

0.50c

[99], [100], [101]

OCT2

7.42±2.84

NEb

NEb

OCT3

NRd

NRd

0.10c

Transporter

a Data

are presented as pmol/mg protein ± SD
= not expressed in this tissue in humans
c Values estimated from Figure 4 in reference [101], expressed in ileum only
d NR = not reported
b NE

Table taken from reference [1]
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[25]
[101]

Human OCT1, OCT2, and OCT3 share overlapping substrate specificity, which
may be due to a number of factors including having significant sequence similarity (70%
identical) and similar two-dimensional structure (12 membrane spanning alpha helices)
[6]. Strong evidence has shown OCTs bind to hundreds of clinically important
compounds, and as a result of this polyspecificity, their function impacts the
pharmacokinetic and dynamic effects associated with commonly prescribed medications
(e.g. cimetidine, metformin), as well as complications arising from drug-drug interactions
(DDI) [102]. Clinical studies have shown a 1.2-1.7 fold increase in metformin AUC and an
overall decrease in its renal elimination when co-administered with the OCT2 inhibitors
cimetidine, trimethoprim, or lansoprazole [103–105]. Similarly, in vivo studies in rats found
altered pharmacokinetics and decreased elimination of cationic medications were
associated with downregulation of OCT2 [106,107]. Additional clinical studies have shown
that OCT1 genetic polymorphisms can also contribute to variations in patient response to
metformin, particularly its efficacy and distribution [108,109]. Finally, studies utilizing
OCT3 knockout mice found decreased bioavailability and decreased elimination of orally
administered metformin [110,111]. Thus, all three OCT paralogs may differentially impact
the overall pharmacokinetics and efficacy of metformin according to their tissue
expression and polarity of membrane targeting (Figure 1.1).
By virtue of where they are expressed, OCTs have clearly exhibited a strong
presence in potentiating pharmacokinetic properties of numerous drugs and DDIs. Major
regulatory agencies, including the U.S. Food and Drug Administration (FDA) and
European Medicines Agency (EMA), through their guidances strongly suggest the
importance of in vitro testing of new drug candidates to determine their renal elimination
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and drug-drug interaction potential, specifically emphasizing their interaction likelihood
with the SLC22 members OCT2, OAT1, and OAT3 [112,113]. From recent discussions
within the International Transporter Consortium, OCT1, is an emerging clinically important
transporter that soon could be included in the guidances due to an increasing number of
studies showing strong associations between OCT1 polymorphisms and pharmacokinetic
and pharmacodynamic drug effects [114–119]. As such, conducting additional
pharmacogenomic studies may be strongly advised for new drugs that are substrates of
OCT1, particularly those with narrow therapeutic windows. It would not be surprising to
soon see OCT3 added to this list as well.
Despite this broad evidence supporting the significance of the role of OCT1, OCT2,
and OCT3 in the translocation of scores of endogenous and exogenous compounds, little
to nothing is known regarding the biochemical nature of the interactions between known
substrates/inhibitors and the transporters. In order to establish a strong predictive model
for DDIs and optimize drug delivery while minimizing harmful side effects for novel drug
candidates in the pharmaceutical pipeline, identifying the three-dimensional structure,
substrate-binding pocket, as well as the critical amino acid residues involved in OCTsubstrate interactions is paramount [120]. The most direct method to achieve this overall
objective is through the utilization of x-ray crystallography. However, to date, only a limited
number of membrane bound proteins have been successfully crystallized, none of which
includes any members of the SLC22 family [121]. Therefore, it is of utmost importance to
resort to alternative approaches. To that end, the construction and application of
homology models that are based on the experimentally determined high resolution
structure of related proteins has served as a promising option for characterizing
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transporter structural properties, substrate-transporter interactions, and mechanisms of
substrate translocation [121–123].
1.C

CURRENT SCOPE OF MOLECULAR MODELING
Initial attempts to understand the nature of transporter-substrate interactions for

organic cation transporters were initially performed on rat Oct1 and Oct2 [124,125].
Preliminary knowledge of secondary structure derived from hydropathy sequence
analysis was used in conjunction with identified evolutionarily conserved amino acid
regions and amino acid physicochemical properties, in order to identify potential critical
regions for ligand binding [124,125]. Since OCT ligands carry a positive charge, acidic
amino acids in these regions were targeted. For example, the aspartic acid at position
475, located in TMD 11, which is conserved in OCTs, but not OATs, was subjected to
mutagenesis resulting in changes in rat (r)Oct1 transport activity and suggesting its
potential significance as an important binding site [124]. Follow up studies were
performed to determine the amino acids responsible for the higher affinity of the steroid
hormone, corticosterone, for rOct2 compared with rOct1 [126,127]. Through a series of
mutations involving the exchange of amino acids between the two paralogs and the
measurement of different transporter properties, amino acids that may be critical for
substrate-transporter interactions were identified (Table 1.5) [125]. Thus, what specifically
distinguishes the OCT paralogs in terms of substrate affinity and/or specificity may be
related to amino acid differences in these critical regions.
Despite some apparent success utilizing 2-D models as the basis for establishing
potential critical binding residues, a significant limitation was the inability to determine the
binding pockets for substrate-transporter interaction. This limitation can be addressed
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through the use of more advanced technologies such as X-ray crystallography and NMR.
However, these methods also have their own limitations such as requiring pure sample
preparations in concentrations significantly higher than how much they normally appear
in their natural system. For using NMR to determine protein structure, there also exists
the hurdle of size limitation, with current technology only being able to process protein
masses up to 15 kD [128]. Nevertheless, obtaining such structural knowledge can be
extremely useful for designing effective and safe therapeutic medications [122],
understanding disease caused by protein polymorphisms [129], as well as optimizing the
process of elucidating the biochemical interactions of proteins [128].
Comparative or homology modeling has gained traction in bridging the gap
between sequence and structural space, as it allows investigators to obtain a reasonable
prediction of the tertiary structure for proteins that are difficult to crystallize or for which
structure determination via experimental methods like NMR is not feasible. Homology
modeling relies on the basis that two proteins that are evolutionarily similar in sequence
also exhibit analogous structures [130]. The protein with the known structure serves as
the template for the construction of a model for the protein for which the tertiary structure
is not known. According to Protein Data Bank [131], the repository of experimental
structures, the total number of experimental protein structures available to date has
reached 83,975, however, the rate at which structures are solved experimentally is still
outpaced by the rate at which new proteins are discovered [132]. This fact adds enhanced
emphasis to the importance of utilizing homology modeling as a technique that can assist
in the drug discovery process by aiding the study of the biochemical basis of ligandprotein interactions, providing novel insight to processes impacting substrate specificity,
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as well as elucidating structure-function relationships [122]. The degree of structural
insight provided by homology modeling relies heavily on the degree of sequence similarity
between the template and target protein [133]. In general, models derived by sequence
identities > 30% are deemed homologous and presumed to share a common 3-D
structure based on their evolutionary divergence [134]. Models based on sequence
identities of 25-50% are considered sufficient for informing site-directed mutagenesis
experiments, and those >50% are considered reliable for structure-based drug design,
while sequence identities below 15% are considered suspect for structural modeling
[134]. The basic steps for homology modeling includes the following: template selection,
template-target alignment, model building, and model evaluation [135]. This process has
more recently been coupled with molecular docking in order to optimize models for
protein-ligand interaction studies as well as structure-based drug design [136].
Template selection begins through the utilization of a sequence search program
(e.g. BLAST). Interestingly, although sharing >40% sequence similarity is considered a
reasonable template for most target proteins, many SLC family members share the same
secondary structure (same number of folds) in spite of their low overall sequence
similarity (~10%) [137]. Next, the template and target protein sequences are aligned
based on their evolutionarily conserved regions by the commonly used program ClustalX
[138]. Sources of dissimilarity may be due to the presence of large exposed loops
between transmembrane domains. For optimal homology modeling, especially for
challenging targets like SLC22s, it is thus important to visually inspect the results, remove
such loop sequences, and perform any necessary manual adjustments to minimize the
gaps in the sequence [135]. Once the template-target alignment is generated, 3-D model
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building is initiated based on the template protein structure. The frequently used program,
MODELLER (University of California at San Francisco, San Francisco, CA) [139],
depends on satisfaction of spatial and stereochemical constraints derived from the
template structure guided by the template-target alignment [123]. The top ranked models
are then subjected to careful visual inspection to refine errors caused by target-template
sequence divergence of the top-ranked models and validated using a variety of different
methods. Such validation methods include the evaluation of stereochemical properties
(e.g. PROCHECK) [140] and the environment of each amino acid in the model with
respect to the environment found in experimentally determined structures (e.g. Z-DOPE)
[141]. Membrane transporters in general pose several challenges for homology modeling
given their diverse transmembrane secondary structure profiles and their relatively low
sequence identities/similarities to related solved crystal structures [135].
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Table 1.4. Summary of the SLC family homology model template recommendationsa.
Template transporter
Family
Name
Function
SLC7
AdiC
Amino acid antiporter

a

SLC10

ASBTNM

Apical sodium-dependent bile acid transporter

SLC15

PepTSO

Peptide transporter

SLC22

High-affinity phosphate importer PiPT

Organic cation/anion/zwitterion transporters

SLC28

vcCNT

Concentrative nucleoside transporter

SLC47

NorM

Multidrug and toxin extrusion (MATE) transporters

Table adapted from reference [142]
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Two transporters, derived from Escherichia coli (E. coli), that were successfully
crystallized, lactose permease transporter (LacY, PDB ID: 1PV6) and glycerol-3phosphate transporter (GlpT, PDB ID: 1PW4) have been used previously to homology
model rat Oct1, rabbit Oct1 and Oct2, and human OCT2 [143–146]. Transport activity for
MPP+ and TEA was measured in mutants of 18 consecutive amino acids in TMD 4 of rat
Oct1 [143]. The rationale behind the mutation strategy was based on the fact that TMD4
contains amino acids on one side of the presumed alpha helix that are conserved within
the three paralogs of OCTs, but not the OATs. The changes observed in transport activity
of MPP+ and TEA identified three amino acid residues (Tyr218, Tyr222, and Thr226)
critical in a proposed binding pocket (Table 1.5). Subsequent homology modeling using
LacY as template appeared to support this contention [143]. Similarly, in a different study,
markedly different affinities for selected substrates between rabbit Oct1 and Oct2 were
demonstrated through site directed mutational studies [145]. Glu447 was found to exert
a marked influence for substrate selectivity in rabbit Oct2. This result was consistent with
a subsequently constructed inward open 3-D homology model derived from GlpT, which
showed Glu447 residing in a hydrophilic cleft of the putative docking region of rabbit Oct2
[145,147]. An additional study was conducted showing that substitutions at Cys451
decreased rabbit Oct1 affinity for choline, which was later shown to reside in the choline
binding domain of a LacY derived homology model [148]. Another group further studied
human OCT2 and tested the interaction potential of several homologous conserved
cysteine residues found within TMD 10 and 11 that were theorized to comprise the
hydrophilic binding cleft [146]. A 3-D homology model was generated for human OCT2
using GlpT as template to help validate their findings showing that Cys474 serves to form
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a transport pathway for the OCT2 substrate TEA [146]. Notably, these studies utilized
homology modeling in an attempt to correlate their mutational study results rather than
using homology modeling and docking to drive the mutational studies. Amino acid
residues deemed critical for substrate-binding resulting from these initial tertiary structurebased modeling studies are summarized in Table 1.5.
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Table 1.5 Summary of critical residues discovered through initial OCT modeling studies.
Topology
Transportera
Model
Template
Critical residue
Substrate
rOct1
2-D
Asp475 (TMD11)
MPP+

a r,

Reference
[124]

rOct1

2-D

-

Ile443, Leu447, Gln448 (TMD 10) MPP+, TEA, Corticosterone

[125]

rOct2

2-D

-

Ile443, Tyr447, Glu448 (TMD 10) MPP+, TEA, Corticosterone

[125]

rOct1

3-D

LacY

Tyr218, Tyr222, Thre226 (TMD 4)

TEA

[143]

rbOct1

3-D

LacY

Cys451 (TMD 10)

Choline

[144]

rbOct2

3-D

GlpT

Glu447 (TMD 10)

TEA

[145]

hOCT2

3-D

GlpT

Cys474 (TMD 4)

TEA

[146]

rat; rb, rabbit; h, human
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While in the aforementioned studies, several potentially important amino acids for
substrate binding were identified, the relatively low sequence identity of LacY and GlpT
with the OCTs (~15%) casts strong doubt as to the exact alignment between the target
and template [134]. A recent comprehensive comparative analysis of key SLC member
sequences was conducted, resulting in updated recommendations for crystal structure
templates in SLC homology modeling [142]. As indicated in Table 1.4, a new protein,
Piriformospora indica phosphate transporter (PiPT) from the major facilitator superfamily
(MFS) that has recently been crystallized is considered as the best available template for
OCT homology modeling studies [149]. Piriformospora indica is a eukaryotic endophytic
fungus that colonizes the roots of several plant species and is involved in enhancing plant
growth [149]. PiPT has been recently shown to be a high-affinity transporter responsible
for improving phosphate nutrition levels in the host plant [150]. PiPT, like hOCTs, has 12
membrane domain spanning alpha helices [149]. There are specific residues at Tyr328
and Trp320 on TMD 7 of PiPT that are highly conserved in the SLC22 family which
suggests a shared substrate-binding mechanism using this helix. PiPT possesses higher
sequence identity with OCTs (~21% identical, 40% similar) than LacY and GlpT, thus
increasing the confidence for guiding mutagenesis experiments. Furthermore, PiPT is
derived from a eukaryotic organism making it evolutionarily more related with the
mammalian OCTs compared to LacY and GlpT which are both derived from a prokaryote
(E. coli). LacY and GlpT were both crystallized in an inward-open state while PiPT was
crystallized in the occluded state which adopts a compact helical arrangement around the
substrate binding site maximizing the possible interactions between the docked ligand
and proposed transporter interaction pocket [147,149,151]. An important feature that
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PiPT possesses that is absent in LacY and GlpT is the intracellular loop between TMD 6
and 7 that is also evolutionarily conserved in OCTs.
Therefore, given the aforementioned information, it would seem prudent that
homology modeling studies in hOCTs be considered using the most recently crystallized
MFS member, PiPT, to elucidate the amino acid residues critical for transporter-substrate
binding interactions in human OCT1 and OCT2.
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CHAPTER 2

RESEARCH OBJECTIVES AND SPECIFIC AIMS

2.A

RESEARCH OBJECTIVES AND HYPOTHESIS
The overarching goal of the current study is to elucidate the critical amino acid

residues for transporter-substrate binding interactions on human (h)OCT1 and OCT2
through in silico molecular modeling techniques (homology modeling and automated
docking), followed by in vitro mutagenesis and kinetic transport experiments. Our
hypothesis is that through the substitution of hOCT1 and hOCT2 amino acids involved in
substrate-transporter interactions, identified by in silico homology modeling with
Piriformospora indica phosphate transporter (PiPT) as template and molecular docking
studies, a change in affinity (Km) of the transporter to its prototypical substrate MPP + will
be produced.

2.B

SPECIFIC AIMS TO ADDRESS HYPOTHESIS

SPECIFIC AIM 1
To identify critical amino acid residues for substrate-binding in hOCT1 and hOCT2
a. An in-silico 3-dimensional (3-D) predictive homology model of hOCT1 and
hOCT2 will be constructed using Piriformospora indica phosphate
transporter (PiPT) as the model template.
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b. Ligand docking studies will be conducted using the organic cation
transporter model substrate 1-methyl-4-phenylpyridinium (MPP+) to
determine the putative substrate binding pocket(s) for hOCT1 and hOCT2.
c. Putative amino acid residues involved in MPP + substrate-transporter
interaction will be identified.
SPECIFIC AIM 2
To confirm the validity of the predicted critical residues associated with hOCT1 and
hOCT2 substrate recognition determined through 3-D homology modeling and ligand
docking, a series of steps to examine changes in substrate affinity will be performed
including:
a. The introduction of conservative and non-conservative substitutions that
alter predicted critical amino acid residues using site-directed mutagenesis.
b. The creation of stably transfected cell lines expressing hOCT1 and hOCT2
mutants.
c. Kinetic analysis to determine the affinity of hOCT1 and hOCT2 mutants for
the prototypical substrate MPP+.
d. Confirming membrane targeting for hOCT1 and hOCT2 mutants with
attenuated transport activity (e.g. via immunodetection with Western blots
or immunocytochemistry).

31

SPECIFIC AIM 3
To further evaluate the generated in silico hOCT1 and hOCT2 models, substrates
with disparate structures will be docked to determine the presence of alternative and/or
additional critical amino acid residues in the binding pocket(s). This will be evaluated by:
a. Performing additional docking studies using OCT substrates with varying
structures (e.g. epinephrine, tetrapentylammonium (TPA), serotonin,
metformin, cimetidine).
b. Comparisons of proposed critical amino acid residues mediating
transporter-substrate interactions across human OCT1, OCT2 (current
work) and OCT3 (previous work).
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CHAPTER 3

IDENTIFYING STRUCTURAL ELEMENTS OF HUMAN ORGANIC CATION
TRANSPORTER 2 (SLC22A2) MEDIATING SUBSTRATE-TRANSPORTER
INTERACTIONS
3.A

INTRODUCTION
Transporters, which have garnered much interest in the field of clinical

pharmacology and pharmaceutics, are extensively expressed throughout the body. They
serve a variety of functions that include the uptake and elimination of both endogenous
and exogenous compounds. One group of transporters that recognize a broad-spectrum
of small organic compounds with positive charge are the organic cation transporters
OCT1, OCT2, and OCT3 [6]. These transporters belong to the solute carrier 22 family
(SLC22) of the major facilitator superfamily (MFS) and share high sequence homology
[6,152]. The OCTs are proposed to have 12 membrane-spanning alpha helical domains,
a large extracellular glycosylated loop between transmembrane domains (TMD) 1 and 2,
a large intracellular loop between TMDs 6 and 7, and intracellular N- and C-terminal
domains.
Due to their expression in intestine, liver, and kidney, the OCTs exert significant
impact on the pharmacokinetic and pharmacodynamic effects relating to the safety and
efficacy of many common medications, as well as on the resulting complications arising
from drug-drug interactions. Both the U.S. Food and Drug Administration (FDA) and
European Medicines Agency (EMA) have issued guidance documents recognizing the
importance of transporter research in the drug development process [112,113]. The
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guidances define circumstances under which new investigational drugs should be
evaluated in vitro as potential transporter substrates, to project their drug-drug interaction
potential, specifically SLC22 family members including OCT2 (SLC22A2), OAT1
(SLC22A6), and OAT3 (SLC22A7) [112]. OCT1 (SLC22A1) is an emerging clinically
important transporter under consideration for addition to the guidances.
Despite the vast literature base detailing the hundreds of different endogenous and
pharmaceutical substrates and inhibitors associated with OCTs, the biochemical nature
of their binding interactions has yet to be determined. The approach to better
understanding the intricacies of drug transport and ultimately optimizing drug delivery and
elimination while reducing toxicity lies in 1) revealing the structural foundations of the
substrate binding region(s), 2) understanding how the variety of substrates bind to
this(ese) region(s), and 3) how substrate binding contributes to its translocation across
membranes [120]. The simplest and most direct approach to achieving this goal is to
determine

the

structure

of

the

transporter-substrate

complex

through

x-ray

crystallography. However, to date, no crystal structure of any of the OCTs has been
successfully solved. An alternative strategy involves the construction of a homology
model using the known crystal structure of a closely related transporter protein. The
homology model can then be used to dock substrates in silico to identify putative binding
pocket(s) and critical residues participating in the binding interactions between substrate
and transporter.
Previous homology modeling of rabbit Oct1 and Oct2, and human OCT2 based on
the tertiary structure of the lactose permease (LacY) and glycerol-3-phosphate (GlpT)
transporters from E. coli has been performed [143,146,148,153]. However, it is important
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to note that these bacterial transporter templates exhibit extremely low (~15%) sequence
identity with mammalian (human) OCTs. Generally, sequence identities of 25-50% are
considered necessary to generate models useful for informing site-directed mutagenesis
experiments, with sequence identities below 15% considered suspect for structural
modeling [134]. Recently, the crystal structure of a more closely related MFS member,
the Piriformospora indica phosphate transporter (PiPT), has been solved [149]. PiPT
exhibits ~21% sequence identity with human OCT1, OCT2, and OCT3, and, therefore,
should provide a better template for generating homology models of these transporters.
Thus, in order to elucidate the critical amino acid residues for transporter-substrate
binding interactions on hOCT2, a series of in silico and in vitro experiments were
conducted. Initially, a novel 3-D homology model for hOCT2 was developed using the
known crystal structure PiPT. The PiPT structure represents the transporter in its
occluded state, with endogenous ligand bound. The resulting hOCT2 homology model
was then used to dock the prototypical substrate, MPP +, to identify the binding pocket(s)
and potential substrate interacting residues located within it. Next, mutant hOCT2
transporters containing conservative and non-conservative substitutions of interacting
residues predicted from the generated model were constructed through site-directed
mutagenesis. Subsequently, cell lines stably expressing the individual mutant hOCT2
transporters were established and used to conduct kinetic transport assays (saturation
analysis) to determine any changes in transporter function and affinity (K m) for MPP+.
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3.B

MATERIAL AND METHODS

3.B.1 Chemicals and reagents
Tritiated [3H] MPP+ was purchased from PerkinElmer Life and Analytical Science
(Waltham, MA) and unlabeled MPP+ was obtained from Sigma-Aldrich (St. Louis, MO).
Quinine monohydrochloride dihydrate was purchased from Acros Organics (Fair Lawn,
NJ). Bio-Rad protein assay dye reagent concentrate was purchased from Bio-Rad
Laboratories, Inc. (Hercules, CA). Specific primers for mutation reactions were purchased
from Integrated DNA Technologies (IDT; Coralville, IA). QuikChange Lightning SiteDirected Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA).
Lipofectamine® 2000 Transfection Reagent and Prolong diamond antifade mountant with
DAPI was purchased from ThermoFisher Scientific (Waltham, MA). QIAprep spin
miniprep kit and QIAprep spin midiprep kit [154] were purchased from QIAGEN Inc.
(Germantown, MD). GoTaq green master mix was purchased from Promega (Madison,
WI). Opti-Mem reduced serum and Dulbecco’s modified eagle’s medium were purchased
from Life Technologies (Carlsbad, CA). Abcam plasma membrane protein extraction kit
(ab65400) was purchased from Abcam (Cambridge, United Kingdom). Rabbit antiSLC22A2 polyclonal antibody (GTX46838) was purchased from GeneTex (Irvine, CA),
anti-rabbit IgG alkaline phosphatase (AP)-linked antibody (7054S) was purchased from
Cell Signaling Technology (Danvers, MA), goat anti-actin polyclonal antibody (SC-1616),
donkey anti-goat IgG-AP (sc-2022), goat anti-rabbit IgG- fluorescein isothiocyanate
(FITC) (SC-2012), and donkey anti-goat IgG-FITC (SC-2024) were purchased from Santa
Cruz Biotechnology (Dallas, TX). Nitro-blue tetrazolium and 5-bromo-4-chloro-3'-
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indolyphosphate (NBT/BCIP) and complete mini protease inhibitor cocktail tablets were
purchased from Roche Diagnostics (Mannheim, Germany).
3.B.2 Homology modeling and docking studies
The hOCT2 (UniProt ID: O15244) and PiPT (PDB ID: 4J05) sequences were
obtained from the Universal Protein Resource (UniProt) and PDB, respectively [131,155].
Protein sequence alignment of PiPT and hOCT2 was performed with ClustalX and
followed by sequence curating via loop removal and manual refinement of gaps based on
the transmembrane domains observed in the PiPT crystal structure and predicted for
hOCT2 using ICM Browser (Molsoft LLC) and Phobius (Stockholm Bioinformatics
Center). Amino acid sequence alignment of hOCT2 with the template and subsequent
generation of a population of 100 homology models were performed using ClustalX 2.1
and MODELLER v9.17, respectively. Using SYBL-X 2.1, a structural cavity search was
conducted for each model to identify putative binding pocket(s). The hOCT2 substrates,
MPP+, epinephrine, serotonin, cimetidine, tetrapentylammonium (TPA) and metformin,
and inhibitor, quinine, (Figure 3.1) were sketched and energy-minimized using SYBL-X
2.1 (Tripos Force Field, Gasteiger-Hückle charges distance-dependent dielectric constant
= 4.0 D/Å) and docked into each of the 100 models within a 15 Å radius of Trp355 (a
residue present within the identified binding pocket) using GOLD Suite 5.5. A favorable
model was selected based on the combined MODELLER discrete optimized protein
energy (DOPE) score, GOLD docking score, and Ramachandran plot results. The DOPE
score, accounting for spherical and finite shape of the native structures, helps to
determine the quality of the protein models. The GOLD score evaluates the interactions
of the docked substrate within the proposed binding pocket(s). Ramachandran plots were
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used to help visualize energetically allowed regions for backbone dihedral angles against
amino acid residues in the protein structure. A model with more than 90% of amino acids
located in the favorable regions of a Ramachandran plot is generally considered an
acceptable model. High resolution images were obtained using PyMOL v1.8.and SYBLX-2.1.
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Figure 3.1 Chemical structures of compounds docked into hOCT2 homology
models.
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3.B.3 Bacterial transformation
Plasmid DNA (pcDNA3-hOCT2) was transformed through the following steps:
adding 10 ng of DNA to 50 µL of DH5alpha competent cells, incubating on ice for 30
minutes, and then applying heat shock at 42°C for 20 seconds. The mixture was then
added to 950 µL of 37°C preheated LB broth and incubated while shaking (225 rpm) at
37°C for one hour. Afterward, the mixture was plated onto LB agar plates containing
ampicillin (0.1 mg/mL) and incubated overnight at 37°C. The following day, colonies were
picked and grown overnight (with shaking at 225 rpm) in LB broth with ampicillin
(0.1mg/mL) at 37°C. Plasmid DNA extraction was performed using the Qiaprep spin
miniprep kit according to the manufacturer’s recommendations [154]. Bacterial pellets
were resuspended and lysed, followed by the use of spin columns to isolate plasmid DNA
and wash/discard any impurities in the flow through. Eluted plasmid DNA from the column
was stored at -20°C. Plasmid DNA concentration and purity were determined via UV
spectrophotometry.
3.B.4 Point mutation of plasmid DNA
Synthetic oligonucleotide primers containing the desired DNA mutations were
designed using the QuikChange Primer Design program (Agilent Technologies) (Table
3.1). Amino acid substitutions were introduced into the hOCT2 coding sequence via site
directed mutagenesis (QuikChange Lightning Site-directed Mutagenesis Kit) according to
the manufacturer's recommendations. The resulting mutant plasmids were transformed
into XL 10-GOLD ultra-competent cells according to the manufacturer’s protocol and
plated on LB-agar plates with ampicillin (0.1 mg/mL) and incubated overnight at 37°C.
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Colonies were picked, purified, and the presence of the desired mutation was then
confirmed by DNA sequencing.
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Table 3.1 Primers for hOCT2 site directed mutagenesis.
Protein residue Direction
Mutant oligonucleotide (5'→ 3')
Gln242Glu
Forward
GAA CAG TGG GGA TTT TTT ACG AAG TTG CCT ATA CAG TTG G

Gln242Lys

Tyr245Phe

Tyr245Ala

Thr246Ser

Thr246Lys

Tyr362Phe

Tyr362Ala

Reverse

CCA ACT GTA TAG GCA ACT TCG TAA AAA ATC CCC ACT GTT C

Forward

GAA CAG TGG GGA TTT TTT ACA AAG TTG CCT ATA CAG TTG G

Reverse

CCA ACT GTA TAG GCA ACT TTG TAA AAA ATC CCC ACT GTT C

Forward

TTT TTA CCA AGT TGC CTT TAC AGT TGG GCT CCT GG

Reverse

CCA GGA GCC CAA CTG TAA AGG CAA CTT GGT AAA AA

Forward

GAT TTT TTA CCA AGT TGC CGC TAC AGT TGG GCT CCT GGT G

Reverse

CAC CAG GAG CCC AAC TGT AGC GGC AAC TTG GTA AAA AAT C

Forward

TTT ACC AAG TTG CCT ATT CAG TTG GGC TCC TGG T

Reverse

ACC AGG AGC CCA ACT GAA TAG GCA ACT TGG TAA A

Forward

GGA TTT TTT ACC AAG TTG CCT ATA AAG TTG GGC TCC TG

Reverse

CAG GAG CCC AAC TTT ATA GGC AAC TTG GTA AAA AAT CC

Forward

CAC GAG CTC TGT GCT CTT CCA GGG CCT

Reverse

AGG CCC TGG AAG AGC ACA GAG CTC GTG

Forward

CAC GAG CTC TGT GCT CGC CCA GGG CCT CAT CAT G
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Glu448Asp

Glu448Ala

Reverse

CAT GAT GAG GCC CTG GGC GAG CAC AGA GCT CGT G

Forward

GAT CAC AAT GGC CTA TGA TAT AGT CTG CCT GGT CAA T

Reverse

ATT GAC CAG GCA GAC TAT ATC ATA GGC CAT TGT GAT C

Forward

GAT CAC AAT GGC CTA TGC GAT AGT CTG CCT GGT CA

Reverse

TGA CCA GGC AGA CTA TCG CAT AGG CCA TTG TGA TC
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3.B.5 Cell line transfection and maintenance
Mutant transporter expressing CHO cell lines were generated using cationic lipidbased transfection. Briefly, 1μg plasmid DNA was combined with 2 µL Lipofectamine
2000 (Invitrogen), mixed, diluted in 100 µL Opti-MEM (Invitrogen) and applied to CHO
cells at 50-60% confluency in 12-well plates (Corning Inc, Corning, NY). Fresh culture
medium (DMEM/F12) was applied just prior to the addition of transfection agents. After
incubating for 24 hours at 37°C / 5% CO2, the transfection medium was removed and
replaced with fresh medium containing Geneticin (G418; 1 mg/mL) to select for
successfully transfected cells for a period of 14-21 days. Cells viable in the presence of
G418 were transferred to culture flasks and continued to be maintained under antibiotic
selective pressure (250 µg/mL G418).
CHO control, CHO-hOCT2 and CHO-hOCT2 mutant cell lines were maintained in
Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12) with 10% FBS, and 1%
Penicillin/Streptomycin at 37°C with 5% CO2 in 25 or 75mm2 polystyrene flasks. G418
(250μg/mL) was included in the medium for maintaining selective pressure on stablytransfected cell lines. Cells were sub-cultured every 3-4 days and passages 10-40 were
used for experiments.
3.B.6 Cell accumulation assays
Mutant functional screening
The procedure for the cell accumulation assay has been described previously
[68,69]. Briefly, cells were seeded into 24-well tissue culture plates at a density of 1.5×10 5
cells/well in the absence of antibiotics and cultured for 48 hours. Cells were equilibrated
with transport buffer for 10 min (500 µL of Hanks’ balanced salt solution containing
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10 mM HEPEs, pH 7.4). Equilibration transport buffer was replaced with 400 µL of fresh
transport buffer containing 1 µM unlabeled MPP + spiked with trace [3H]MPP+ (0.25 µCi/ml)
in the presence or absence of the inhibitor quinine (200 µM). After incubation for 10
minutes, the cells were immediately rinsed 3 times with ice cold transport buffer, lysed
with 200 µL 1N NaOH, neutralized with 250 µL 1N HCl and 200 µL 10mM HEPES. The
radioactivity in cell lysates was quantified by liquid scintillation counting, and uptake
normalized by the total protein content determined by the Bradford method. The
intracellular accumulation of substrates was reported as picomoles of substrate per
milligram total protein. All uptake data were corrected for background accumulation in
corresponding CHO empty vector cells.
Kinetic assays
The Michaelis-Menten constant (Km) was determined for MPP+ uptake in each of
the generated mutant hOCT2-expressing cell lines via saturation analysis according to
our established protocol [156]. The experiment was carried out in the same way as
described for the functional screening assay with the exception that the equilibration
transport buffer was replaced with 400 µL of fresh transporter buffer containing increasing
concentrations (1-200 µM) of unlabeled MPP+ spiked with [3H]MPP+ (0.25 µCi/ml) and
incubated for a period of 1 minute. After incubation, the cells were immediately rinsed 3
times with ice cold transport buffer and lysed with 1N NaOH, neutralized with 250 µL 1N
HCl and 200 µL 20mM HEPES. The Km estimate, which represents the concentration of
substrate at half maximum velocity of the transporter, was calculated using nonlinear
regression with the enzyme kinetics model in GraphPad Prism 5.0 (GraphPad Software
Inc., San Diego, CA). Individual saturation experiments were repeated at least three times
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with duplicate wells and plotted as mean ± SD. Km estimates were reported as mean ±
SE.
3.B.7 Genomic DNA integration confirmation
Cells were suspended in 500 μL lysis buffer [1 M Tris (pH 8.0), 5 M NaCl, 0.5 M
EDTA, and 10% SDS] containing proteinase K (0.4 mg/mL) and incubated at 55°C while
shaking overnight. Genomic DNA was thoroughly extracted from samples with an equal
volume of phenol/chloroform/isoamyl alcohol (25:24:1) after gentle mixing for 10 min, and
centrifugation for 10 min at 15,000 g. The upper aqueous phase was carefully collected,
isopropanol was added and mixed well, then centrifuged immediately at 15,000 g for 30
min to obtain DNA pellet. The pellet was washed with 70% ethanol, dried, and
resuspended with 50 µL TE buffer [10 mM Tris (pH 8.0), and 1 mM EDTA]. Concentration
of DNA was determined through UV spectrophotometry. Genomic DNA (2 ng), 2x Go-taq
Master Mix (5 μL), as well as 1 μL primer pair mix (T7: 5’- TAATACGACTCACTATAGGG3; hOCT2-REV: 5’- CCAGTGAGGAAGTGCGTAAG -3’) were added together to a final
volume of 20 µL and run in a thermocycler: initial denaturation at 95°C for 5 min, followed
by 30 cycles of: denaturation at 95°C for 2 min, annealing at 50-52°C for 30 seconds, and
elongation at 72°C for 30 seconds. Final elongation step at 72°C for 5 min and held at
4°C. PCR products were loaded into a 1% agarose gel for separation using
electrophoresis at 120 V for 60 min and visualized by UV light following ethidium bromide
staining.
3.B.8 Cell harvest for immunoblotting
Cell lines were harvested according to the Abcam plasma membrane extraction kit
protocol (Abcam, Cambridge, United Kingdom): Briefly, cells were removed by scraping
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in phosphate buffered saline (PBS, Gibco/Invitrogen), centrifuged for 5 minutes at 700 x
g, washed with ice cold PBS, then resuspended with the homogenization buffer and
mixed with a Dounce homogenizer on ice. Afterward, the homogenate was centrifuged at
700 x g for 10 minutes at 4°C. The supernatant was collected and transferred to a new
vial and centrifuged at 10,000 x g for 30 minutes at 4°C. Supernatant (cytosolic fraction)
was collected and stored at -80°C.
3.B.9 SDS-PAGE and Immunoblotting
The cytosolic and plasma membrane fractions were harvested according to the
plasma membrane extraction kit protocol (Abcam). Protein concentration was quantified
using the Bradford method. Samples (20 µg) were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) using the Bio-Rad Mini-PROTEAN
system. Samples were separated using 12% polyacrylamide gels at 170V for 1.5 hours
and then transferred onto polyvinylidene difluoride (PVDF) membrane (Bio-Rad,
Hercules, CA) for 1 hour at 100 mA. Membranes were blocked with 5% BSA in TBST (19
mM Tris base, 137 mM NaCl, 2.7 mM KCl, 0.05% Tween 20, 0.05% sodium azide) for 1
hour. The rabbit anti-OCT2 polyclonal antibody was diluted (1:400) to 2.5 µg/mL in 5%
BSA and the blots probed overnight at 4°C with rocking (18 hours). Three 5-minute
washes were performed with TBST then alkaline phosphatase conjugated secondary
antibody diluted (1:1000) in 5% BSA was added and incubated for 2 hours at room
temperature with rocking. Blots were washed three times for 5 minutes with TBST before
being developed in 0.1 M Tris, 0.1 M NaCl, 5mM MgCl2 phosphatase buffer (pH 9.4)
containing 0.25 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP, Sigma-Aldrich) and
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0.25 mg/ml nitro blue tetrazolium (NBT, Sigma-Aldrich) in the dark. Blots were digitally
scanned.
3.B.10 Immunocytochemistry
Cells were prepared for immunostaining by plating 6 x 10 4 cells/ml onto flame
sterilized 12 mm cover slips (Fisher Scientific) in 6-well plates (Corning, Inc.) overnight in
the absence of antibiotics. Cells (~70% confluent) were washed with PBS, fixed with 4%
paraformaldehyde in PBS for 10 minutes, and permeabilized with 0.01% TritonX in PBS.
The cells were then washed with 1x PBS followed by blocking with 1% BSA in 1x PBS for
1 hour at room temperature. The rabbit anti-OCT2 primary antibody was diluted (1:100)
with 1% BSA in TBST and incubated with the cells at room temperature for 1 hour. Cells
were washed three times for 5 minutes with PBS. FITC anti-rabbit secondary antibody
was diluted to (1:100) in 1% BSA in TBSTA and applied to the cells for 1 hour at room
temperature in the dark. Cells were washed three times for 5 minutes with PBS, placed
on slides with DAPI prolong diamond mounting media and imaged with a fluorescence
microscope (Olympus I51, Olympus, upper Saucon Township, PA).
3.B.11 Green fluorescent protein (GFP) plasmid construction
To make the hOCT2-GFP fusion construct, the full length hOCT2 cDNA fragment
was removed from the isolated library clone, pcDNA3/hOCT2, using the restriction
enzymes Kpn I and Xba I. The fragment was gel isolated and ligated into the pEGFP-C1
vector in frame at the carboxyl terminal end of GFP forming the plasmid pEGFPC1/hOCT2, where “E” denotes “enhanced”. Plasmid construction was performed
commercially (GenScript, Picataway, NJ). The lyophilized GFP plasmid construct, was
resuspended and diluted in TE pH 8, transformed into DH5-alpha cells and DNA extracted
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using the Qiagen miniprep kit. The construct was confirmed by DNA sequencing. Nonfunctional hOCT2 mutants were reproduced in the hOCT2-GFP construct using the
original primers (Table 3.1) and the QuikChange Lightning site-directed mutagenesis kit.
3.B.12 Microscopic imaging
An Olympus IX-70 inverted microscope fit with a 12-bit camera (Olympus, Melville,
NY) was used in order to capture phase contrast and fluorescent images. Fluorescent
images were taken with two second exposures using a 595 nm dichroic long pass filter
(Chroma, Rockingham, VT) illuminated by a mercury arc lamp. The images were
processed using Olympus Microsuite v.5. Confocal fluorescent images were obtained at
the VCU Microscope Core facility using a Zeiss LSM 710 Axio Observer inverted laser
scanning confocal microscope fit with a 63x oil immersion objective. Images were
collected by illuminating samples with a blue diode laser at 405 nm. Images were
processed using Zeiss ZEN 2 Blue edition software (Oberkochen, Germany).
3.B.13 Statistics
The data plots were presented as means ± SD. Dose response curve (Km estimate)
data were reported as mean ± SE for at least n = 3. Km estimates were fit based on the
equation: V0 = Vmax * [S] / (Km + [S]). One-way ANOVA with post-hoc Dunnett’s test was
used to evaluate differences compared to a single control where indicated. Statistical
calculations were performed using Prism 5.0 (GraphPad Software, Inc., San Diego, CA).
A difference was deemed statistically significant if p < 0.05.
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3.C RESULTS
3.C.1 Identification of a hOCT2 model
The hOCT2 peptide sequence (Uniprot ID: O15244) was aligned with the PiPT
template sequence (PDB ID: 4J05) (Figure 3.2) as input for the program MODELLER to
generate 100 initial hOCT2 homology models. Analysis of the initial 100 models identified
a single large cavity in the central region of the transporter as a potential binding pocket.
MPP+ was subsequently docked in this region. After docking MPP + into the generated
hOCT2 models, the most favorable interaction model was selected based on three main
criteria: GOLD docking score, DOPE score, and the total number of clusters.
The genetic optimized ligand docking (GOLD) scoring is essentially a method to
quantify which poses generated for a particular ligand are most likely to occur based on
the interactions present within the transporter. GOLD scores for the top ten most
favorable docked poses of MPP+ in the binding pocket of the hOCT2 models (ranging
from 58.49 to 66.59) were ranked (Table 3.2). Amongst this select group, the top three
model’s GOLD scores had a difference of 0.77 between them, thus were considered to
be virtually identical. The difference between the top and fourth ranked model was
increasingly larger (1.61). The discrete optimized protein energy (DOPE) score accounts
for the shape of native structures which in turn helps to evaluate the quality of the whole
protein structure. The DOPE scores for the top ten models ranged between -48,186 and
-47,268 (Table 3.2). Additionally, the number of homology models which contained a
given substrate pose (number of clusters) was also accounted for in model selection. The
greater the number of models that have a particular substrate pose docked, the higher
the likelihood that the specific pose occurs within the binding pocket. Out of the top 10
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models, models 30 and 64 had 6 clusters, while the rest had 4 or less. Among the top
three ranked GOLD score models, model 64 stood out as having the lowest DOPE score
(-48,030; second lowest DOPE score overall) in conjunction with the highest number of
clusters (6). Taken together, these three selection criteria indicated model 64 as the most
favorable docked model and thus it was selected for subsequent studies. The generated
tertiary structure for model 64 with MPP+ docked in the hypothesized binding pocket is
shown in Figure 3.3. The docked hOCT2 model shows MPP + residing inside a large
central cavity of the 12-membrane spanning alpha helical domains (Figure 3.3).
Ramachandran plots were utilized as a method for determining and visualizing
“allowed regions” for the backbone dihedral angles that make up amino acids in the
generated model. For the amino acids that made up our selected hOCT2 model, 91.4%
were in the most favored regions, 6.1% were in the additionally allowed region, and only
2.4% were in the generously allowed and disallowed regions combined (Figure 3.4). The
most favored regions category was > 90%, thus supporting the selected hOCT2 model
as acceptable.
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Figure 3.2 Sequence alignment of PiPT and hOCT2.
The alignment was constructed with ClustalX, followed by manually refining gaps based
on the transmembrane regions observed in the PiPT crystal structure and predicted for
hOCT2 using Phobius, a topology prediction algorithm. Residues forming the large
extracellular and intracellular loop between transmembrane domain 1 and 2 and
intracellular loop between 6 and 7 of PiPT and hOCT2. The transmembrane domains in
the hOCT2 model (red) and PiPT tertiary structure (blue) are highlighted. “*” indicates
exact sequence match, “:” indicates high sequence similarity, “.” indicates low sequence
similarity
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Table 3.2 Summary of hOCT2 model evaluation scores.
GOLD Rank
1

Model ID
24

Gold score
66.59

DOPE Score
-47676.04688

No. of
Clusters
2

2

12

66.52

-47487.76953

2

3

64

65.82

-48030.84375

6

4

47

64.98

-47691.90625

3

5

2

64.1

-47665.14453

1

6

30

62.73

-47813.59766

6

7

95

61.53

-47268.98438

4

8

100

60.53

-48186.85547

3

9

55

59.64

-47915.82422

4

10

71

58.49

-47584.00781

1
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Figure 3.3 hOCT2 homology model.
The generated 3-D molecular structure of hOCT2 (ribbons) is shown with MPP+ (space-filled) positioned in the putative
binding pocket viewed from (A) profile and (B) top-down angles.
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Figure 3.4 Ramachandran plot for hOCT2 homology model.
Phi and psi indicate backbone conformation dihedral angles of amino acid residues,
representing the rotations of a polypeptide main chain N-Cα and Cα-C bonds. Amino
acids are displayed in different regions: most favored region (red), additional allowed
region (yellow), generously allowed region (light yellow), and disallowed region (white).
Residues depicted in red squares are in the generously allowed and disallowed regions.
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3.C.2 Identifying amino acid residues important for MPP + hOCT2 interaction
Several amino acids were identified that made up the binding pocket (within the
designated 5 Å radius of the substrate) for docked MPP+ in the selected hOCT2 model.
The identified amino acid residues were found in several different TMDs that came
together in the central area forming a large distinct cavity of the transporter—TMD 1:
Phe17; TMD 5: Ile239, Gln242, Val243, Tyr245, Thr246, Val247, Leu249; TMD 7: Trp355,
Ser358, Ser359, Tyr362, Gln363, Gln387; TMD 8: Gln387, Phe388, Ala391, Ile394; TMD
10: Trp407, Met445, Ala446, Tyr447, Glu448, Val450, Cys451 (Figure 3.5). Within the
proposed binding pocket, five amino acids were identified (Gln242, Tyr245, Thr246,
Tyr362, and Glu448) as potential candidates critical for transporter-MPP + binding
interactions. Hydrophobic interactions were found between MPP + and amino acid
residues Gln242, Thr246, and Glu448, and one of the aromatic rings of MPP + was
recognized as forming edge-face-pi and pi-stacking interactions with Tyr245 and Tyr362,
respectively (Figure 3.6 and Table 3.3).
To further evaluate the generated in silico hOCT2 model, known substrates with
disparate structures were optimized and docked into the population of 100 models to
determine the presence of alternative and/or additional critical amino acid residues in the
binding pocket(s). The process involved with selecting the most favorable model for
MPP+, was repeated for each docked substrate. Amino acids identified with the greatest
overlap across the different docked compounds were Tyr245, Ser358, Tyr362, and
Glu448 (Figure 3.7 and Table 3.3). There were several amino acids identified that were
also unique to particular compounds including Thr246 for MPP +; Gln363, Gln387 and
Cys451, for serotonin; Cys474 for TPA; and Asp475 for cimetidine.
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Figure 3.5 3-D rendering of putative binding pocket of hOCT2 with docked MPP+.
Amino acid side chains (white) comprising the binding pocket surrounding the substrate MPP+ (orange) is shown viewed
from (A) profile and (B) top-down angles.
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Figure 3.6 Structure of hOCT2 with MPP + docked.
The docked substrate (MPP+, orange) and the amino acids (white side chains) is shown
localized in the predicted substrate binding pocket of hOCT2.
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Table 3.3 hOCT2 docking interaction summary.
Substrate
MPP+

Cimetidine

Epinephrine

Metformin

Quinine

Gln

Sequence
position
242

Tyr

245

Hydrophobic/Edge-Face Pi

5

Thr

246

Hydrophobic

5

Tyr

362

Pi-stack

7

Glu

448

Hydrophobic

10

Asn

157

H-bond

2

Tyr

245

Hydrophobic

5

Ser

358

H-bond

7

Tyr

362

Pi-stacking

7

Glu

448

H-bond (salt bridge)

10

Asp

475

H-bond (salt bridge)

11

Tyr

245

Hydrophobic

5

Ser

358

H-bond

7

Tyr

362

Pi-stack

7

Glu

448

H-bond (salt bridge)

10

Ser

358

H-bond

7

Tyr

362

Pi-stack

7

Glu

448

H-bond (salt bridge)

10

Phe

24

Hydrophobic

1

Asn

157

H-bond (weak)

2

Amino Acid
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Bond Interaction

TMD

Hydrophobic

5

Serotonin

TPA

Phe

160

Hydrophobic

2

Gln

242

H-bond

5

Tyr

245

Hydrophobic

5

Tyr

362

Pi-stacking

7

Tyr

245

Hydrophobic

5

Ser

358

H-bond

7

Tyr

362

Pi-stack

7

Gln

363

H-bond

7

Glu

387

H-bond (salt bridge)

8

Glu

448

H-bond (salt bridge)

10

Cys

451

H-bond

10

Phe

24

Hydrophobic

1

Phe

160

Hydrophobic

2

Tyr

245

Hydrophobic

5

Cys

474

Hydrophobic

11
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Figure 3.7 Known hOCT2 substrates docked into hOCT2 homology model.
Known hOCT2 substrates (purple or orange) (A) cimetidine, (B) epinephrine, (C) metformin, (D) quinine, (E) serotonin, and
(F) TPA, were docked into their respective favorable hOCT2 models. Proposed interactions of interactions are summarized
in Table 3.3.
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3.C.3 Substitution of hOCT2 amino acid residues in putative binding pocket
We investigated the role of the predicted amino acids in hOCT2-MPP+ interactions
through conservative and non-conservative amino acid substitutions introduced into the
hOCT2 coding sequence to evaluate potential changes in hOCT2 function and affinity for
MPP+. The pcDNA3/hOCT2 plasmid vector map is shown in Figure 3.8. The rationale for
deciding each conservative and non-conservative amino acid substitution was based on
a scheme developed by Bordo et al. which categorizes roughly equivalent amino acid
residues based on their physicochemical properties of their side chains (Figure 3.9) [157].
Substitutions for residues deemed critical were Gln242Glu, Tyr245Phe, Thr246Ser,
Tyr362Phe, and Glu448Asp (conservative); and Gln242Lys, Tyr245Ala, Thre246Lys,
Tyr362Ala, and Glu448Ala (non-conservative) (Tables 3.4, 3.5 and 3.6). All hOCT2
mutants were confirmed by DNA sequencing prior to generating stable cell lines. Figure
3.10,

depicts

a

representative

DNA-oligonucleotide

duplex

and

sequencing

chromatogram in which TAC, coding for Tyr362 in wildtype hOCT2, was changed to TTC,
coding for the hOCT2 mutant Tyr362Phe.
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Figure 3.8 pcDNA3/hOCT2 vector map.
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Figure 3.9 Suggested guidance for amino acid residue conservative substitution.
Roughly equivalent amino acid residues categorized based on physiochemical properties into five subgroups.
Diagram is an adapted figure from reference [157]
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Table 3.4 Summary of hOCT2 residue substitutions.
Substitution
Residue

Conservative

Non-Conservative

Gln242

Glu

Lys

Tyr245

Phe

Ala

Thr246

Ser

Lys

Tyr362

Phe

Ala

Glu448

Asp

Ala
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Table 3.5 hOCT2-MPP+ interaction based conservative substitutions.
Sequence
Amino Acid
Codon Mutant Codon
Substitution
position
Gln
242
CAA
GAA
Gln → Glu
Tyr

245

TAT

TTT

Tyr → Phe

Thr

246

ACA

TCA

Thr → Ser

Tyr

362

TAC

TTC

Tyr → Phe

Glu

448

GAG

GAC

Glu → Asp
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Table 3.6 hOCT2-MPP+ interaction based non-conservative substitutions.
Sequence
Amino Acid
Codon
Mutant Codon
Substitution
position
Gln
242
CAA
AAA
Gln → Lys
Tyr

245

TAT

GCT

Tyr → Ala

Thr

246

ACA

AAA

Thr → Lys

Tyr

362

TAC

GCC

Tyr → Ala

Glu

448

GAG

GCG

Glu → Ala
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Figure 3.10 Representative sequencing chromatogram for hOCT2 mutants.
(A) DNA template-primer duplex for hOCT2 Y362F. Chromatogram for (B) hOCT2
wildtype and (C) hOCT2 Y362F are shown with triplet codon corresponding to mutation
site highlighted.
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3.C.4 Critical amino acid confirmation through kinetic assays
In functional screening assays evaluating [3H] MPP+ transport (Figure 3.11), wildtype hOCT2 demonstrated a 4.5-fold higher uptake of MPP + compared to mock
expressing (pcDNA3) background control cells (15.7 ± 0.4 pmol mg protein -1 10 min-1 vs.
3.5 ± 2.7 pmol mg protein-1 10 min-1). Quinine (200 µM), a known inhibitor for OCTs,
virtually abolished hOCT2 mediated MPP+ transport. Two non-conservative mutants,
hOCT2 Glu242Lys and Tyr362Ala, and one conservative mutant, hOCT2 Tyr362Phe,
resulted in a complete loss of MPP+ transport activity (Figure 3.11). All other mutants
retained some level of transport activity and were subjected to saturation analysis in order
to estimate Km (Figure 3.12, Table 3.7).
The affinity of MPP+ determined for wildtype hOCT2 was comparable to values in
prior studies (Km = 19.7 ± 3.4) [158]. When comparing the Km estimates for hOCT2
mutants against wildtype hOCT2, only the non-conservative substitution Tyr245Ala
resulted in a significant change in affinity for MPP +. The mutants Gln242Glu, Tyr245Phe,
Thr246Ser, Thr246Lys, Glu448Asp, Glu448Ala, and Asp475Glu all demonstrated no
significant change in affinity for MPP +.
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Figure 3.11 Functional screen of CHO-hOCT2 wild type and mutant expressing cell
lines.
CHO cells were treated with transport buffer containing 1 µM [ 3H] MPP+ (0.25 µCi/mL) in
the absence or presence of inhibitor (quinine) for 10 min. Conservative and nonconservative mutations appear above original amino acid position. Data shown as
duplicate wells ± SD. ** denotes p<0.01; *** denotes p<0.001; compared against wild type
control by one-way ANOVA followed by post-hoc Dunnett’s t-test.
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Figure 3.12 Representative dose response curves for wild type and mutant hOCT2.
Michaelis-Menten kinetics of [3H] MPP+ transport (1–200 µM) for hOCT2 and hOCT2
mutants in stably transfected CHO cells.
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Table 3.7 Summary of Km estimates for hOCT2 constructs.
hOCT2 Transporter
WT

Km (µM)
19.7 ± 3.4

Gln242Glu

31.9 ± 6.2

Tyr245Phe

22 ± 7.5

Tyr245Ala

36.5 ± 5*

Thr246Ser

15.5 ± 2.8

Thr246Lys

27.4 ± 12.3

Glu448Asp

17.9 ± 3.6

Glu448Ala

17.2 ± 3.8

Asp475Glu

13.5 ± 4

Mean Km estimates acquired from at least 3 experiments ± SE.
* denotes p < 0.05 compared against wild type control by oneway ANOVA followed by post-hoc Dunnett’s t-test.
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3.C.5 Genomic integration of non-functional hOCT2 mutant constructs
To eliminate failed genomic DNA integration as an explanation for the lack of
transport activity in non-functional hOCT2 mutants, genomic DNA was extracted and PCR
amplified using the primers T7 and hOCT2 REV, that flanked 5’ and 3’ ends of the hOCT2
coding sequence of the pcDNA3 plasmid (hOCT2 amplicon ~1.8 kb). PCR products of
the expected size (~1.8 kb) were obtained for wildtype hOCT2 and all hOCT2 mutants
(Gln242Lys, Tyr362Phe, and Tyr362Ala), while no product was observed for negative
controls (water and pcDNA3) demonstrating that all hOCT2 plasmids had been
successfully integrated (Figure 3.13).
3.C.6 Immunodetection of non-functional hOCT2 mutants
To investigate the translation and membrane targeting for hOCT2 mutants that
failed to demonstrate MPP+ transport, Western blotting was performed on isolated
cytoplasmic and plasma membrane fractions from each mutant-expressing cell line using
hOCT2 polyclonal antibody (Figure 3.14). Protein bands were observed at the expected
position for wildtype hOCT2 (~62 kD), however, a similar band was also seen for CHO
empty vector membrane fraction. Detection for β-actin was consistently observed (~43
kD) in all experiments (Figure 3.14).
An alternative method for evaluating membrane targeting of non-functional hOCT2
mutants was pursued. The same antibodies used to probe for hOCT2 in earlier Western
blot studies were also used for immunocytochemistry experiments. Cells expressing
wildtype pcDNA3/hOCT2 constructs showed strong cytosolic fluorescence for both actin
and hOCT2 staining, with no detectable signal in the nucleus (Figure 3.15). Strong
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membrane localization, however, was not present in any of the observed cells. Control
transfections (lipofectamine only) showed no fluorescent signal (data not shown).
3.C.7 Membrane targeting of hOCT2-GFP fusion construct
The full length hOCT2 cDNA fragment was gel isolated and ligated into vector
pEGFP-C1 forming the plasmid pEGFP-C1/hOCT2 containing hOCT2 fused in frame to
the carboxyl terminal of GFP (Figure 3.16). CHO cells expressing the hOCT2-GFP fusion
construct showed strong fluorescence within the cytosol and lack of signal in the nucleus
(Figure 3.17). This pattern is consistent with an intact GFP fusion construct versus
expression of “free” GFP. However, no noticeable fluorescence at the plasma membrane
was observed. Control transfections (lipofectamine only) showed no fluorescent signal
(data not shown). In order to have a reference of the membrane localization of OCTs,
MDCK cells stably transfected with a rat Oct2-GFP fusion construct from a previous study
were grown and observed [159] (Figure 3.18).
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Figure 3.13 PCR analysis of genomic DNA isolated from hOCT2 cell lines.
Confirmation of successful genomic integration of mutant hOCT2 constructs that lacked
transport activity. Lanes: (1) water, (2) pcDNA3, (3) hOCT2, (4) hOCT2 Gln242Lys, (5)
hOCT2 Tyr362Phe, and (6) hOCT2 Tyr362Ala.
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*
†

Figure 3.14 Western blot of CHO cell lysates probing for hOCT2.
Lanes: (1) Protein size standard, (2) mock cytosolic fraction, (3) mock membrane fraction,
(4) hOCT2 cytosolic fraction, (5) hOCT2 membrane fraction.
†, denotes actin; *, denotes expected hOCT2 size.

76

Figure 3.15 Immunocytochemistry of CHO-hOCT2.
CHO cells expressing hOCT2 were probed with anti-actin (A) or anti-hOCT2 (B)
antibodies followed by FITC conjugated secondary antibody and observed under
fluorescent microscopy (40x magnification).
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Figure 3.16 pEGFP-C1/hOCT2 fusion protein vector map.
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Figure 3.17 Expression patterns of pEGFP-C1/hOCT2.
CHO cells transfected with pEGFP-C1/hOCT2 were fixed, permeabilized, and mounted
at 24 hours post transfection then viewed under confocal microscopy: (A) phase contrast,
(B) GFP, (C) DAPI, and (D) merge. Scale bar = 20 µm
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Figure 3.18 Expression of pEGFP-C3/rOct2 in MDCK cells.
MDCK cells stably transfected with pEGFP-C3/rOct2 were thawed, grown in culture for
48 hours, then observed by fluorescence microscopy (40x magnification). Observed cells
were used in a study performed in reference [159].
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3.D

DISCUSSION
The broad structural substrate diversity of the OCTs make them highly susceptible

sites

for

potentially

harmful

drug-drug

interactions.

Therefore,

an

increased

understanding of the biochemical nature of the interactions between transporter and
substrates could provide a prevailing advantage in improving the prediction of drug
interactions involving these membrane transporters. Recently, increased efforts have
been devoted towards better understanding the biochemical interactions between
transporter and substrate among organic cation transporters [124,125,146,148,153].
Several studies utilized hypothesized 3-D structures of their target transporter (e.g. rat
Oct1, rabbit Oct1 and Oct2, and hOCT2) in order to confirm experimentally predicted
critical residues [143,146,148,153] (Table 1.5 in Chapter 1). These early studies
generated homology models of OCTs based on the solved crystal structures of
prokaryotic MFS transporters (from E. coli). Although the studies provided information on
the structural details for OCTs that were previously unknown, the templates they used to
generate models (i.e. LacY, GlpT) were limited in the fact that they share a low sequence
identity with mammalian (human) OCTs (~15%) perhaps due to their prokaryotic origin.
Therefore, in the current study, homology models of the tertiary structure of hOCT2
were generated using the known crystal structure of PiPT serving as the template. PiPT,
also a member of the MFS, was chosen as the designated template due to a number of
factors including its relative sequence homology to the hOCTs (~21% identical, 40%
similar), eukaryotic origin (Piriformospora indica), and the fact that it was crystallized in
the occluded state. The occluded conformation grants the transporter maximum binding
interaction sites for bound ligands. After docking MPP + into the generated hOCT2 models,
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amino acid residues were identified that formed the putative binding pocket (within a 5 Å
radius surrounding the substrate) (Figure 3.5). This approach required that several
assumptions be made during the in silico model building process including that adequate
structural similarity exists between the crystallized tertiary structure of PiPT and hOCT2
and that the presence of water molecules in the occluded binding pocket was negligible
and therefore not considered during the docking analysis. All models were generated
based on PiPT and the hOCT2 protein sequence with transmembrane domains globally
energy minimized.
Amino acid residues deemed “critical” for hOCT2-MPP + binding interactions were
identified in silico based on substrate proximity and interaction types (Table 1.5). Within
the proposed binding pocket, hydrophobic interactions were identified between MPP + and
amino acid residues Gln242, Thr246, and Glu448, and one of the aromatic rings of MPP +
was found to be involved in edge-face pi and pi-stacking interactions with Tyr245 and
Tyr362, respectively. Subsequently, stably transfected CHO cells expressing hOCT2
mutants were established and utilized for a series of in vitro kinetic assays to confirm their
role in substrate binding. From the functional screening study, transport activity of MPP +
was absent for both conservative and non-conservative substitutions of Tyr362, and for
the non-conservative substitution of Gln242 (Figure 3.11). Because MPP + transport was
lacking for both conservative and non-conservative substitutions at Tyr362, this
suggested that it may be a critical site for substrate binding. This result correlates with the
MPP+ docking data where Tyr362 was predicted to participate in the strongest substrate
interaction (pi-pi stacking). However, the loss of transport activity with the conservative
phenylalanine substitution, where the only structural difference is a loss of an aromatic
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hydroxyl group, suggests that the hydroxyl group in Tyr362 may mediate additional
important interactions with other residues within the binding pocket beyond pi-pi stacking
with the substrate, thus playing a significant role in forming the structure of the binding
pocket. When the hydroxyl is absent, as in the Tyr362Phe mutant, the residue may exist
in a different spatial conformation that makes it less accessible for substrate-pi-stacking
interactions. For hOCT2 mutants retaining MPP + transport function, only Tyr245Ala
demonstrated a significant decrease in affinity for the substrate compared to wildtype
(Table 3.7). As such, Tyr245 also may be deemed an important site for hOCT2-MPP +
interaction. To briefly summarize, these initial findings suggest that Gln242, Tyr245, and
particularly Tyr362 may be important for hOCT2-MPP+ interactions within the proposed
binding pocket. Tyr362 demonstrates the strongest case for importance considering both
its conservative and non-conservative substituted mutants eliminated transporter activity
for MPP+.
There are several explanations for the hOCT2 mutants (Gln242Lys, Tyr362Phe,
and Tyr362Ala) that exhibited complete loss of MPP+ transport activity. The specific
amino acid may be a critical residue for transporter-MPP + substrate interactions and thus
when substituted leads to a complete absence of MPP + accumulation. Alternatively, the
proposed transporter-binding pocket conformation could be altered as a result of the
mutated residue. Another possibility is that transfection was not successful and therefore
cDNA integration into the genomic DNA would be absent. Finally, the amino acid could
be critical for maintaining the tertiary and quaternary structure of the transporter and when
mutated could lead to a misfolded protein that is subsequently degraded rather than
trafficking to the cell membrane following translation.
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Genomic integration of intact cDNA for hOCT2 mutants was confirmed by PCR
and gel electrophoresis (Figure 3.13) which ruled out a failed transfection. In order to
confirm that inactive mutant hOCT2 transporters were translated and inserted into the
plasma membranes of transfected mammalian cell lines Western blotting was performed.
Transporter protein detected in the cell membrane fraction of nonfunctional mutants
would suggest that the wildtype amino acid is likely a critical residue for interactions with
MPP+. However, in this study, the polyclonal hOCT2 antibody failed to discriminate
between CHO mock and hOCT2 transfected cells (Figure 3.14). Additionally, the antibody
did not appear to bind specifically to hOCT2, as signal was detected at the expected
position in membranes prepared from CHO mock, as well as from wildtype hOCT1 or
hOCT3 expressing cells (data not shown). The consistent detection of a clear, single band
for actin ruled out any issues related to assay technique. When hOCT2 was probed in
subsequent immunocytochemistry experiments using the same polyclonal hOCT2
antibody, no consistent fluorescent signal localized in the plasma membrane of CHO cells
expressing hOCT2 was observed indicating the issue was related to the commercial
hOCT2 antibody’s lack of specificity. Thus, no conclusions could be drawn from these
experiments.
Previous studies successfully demonstrated plasma membrane targeting when the
transporter sequence for rOct1 or rOct2 was fused in frame to the C-terminus of GFP and
transfected into MDCK cells [159,160]. A similar approach was performed in the current
study by fusing the coding sequence of hOCT2 to the C-terminus of GFP to evaluate
membrane targeting of non-functional hOCT2 mutants. However, we failed to observe
targeting at the plasma membrane in CHO cells transiently transfected with the wildtype
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hOCT2-GFP fusion construct. Instead we observed a consistent pattern of fluorescence
in the cytosol surrounding the nucleus. The discrepancy in what was observed compared
to the prior studies may be due to differences associated with the cell line used (MDCK
vs CHO cells). A future study involving the transfection of our pEGFP-hOCT2 fusion
construct into MDCK cells should be considered.
In the analysis of docking known substrates with varying structures into the hOCT2
homology models, interacting amino acids were identified to be unique for some
substrates and shared for others (Table 3.3). For example, Glu448 was amongst the
residues identified that was shared across many substrates including MPP +, cimetidine,
epinephrine, metformin, and serotonin. This residue corresponds to Glu477 in rabbit Oct2,
which was identified as being critical for mediating TEA transport and verified by a rabbit
Oct2 homology model based on GlpT [153]. Glu447/Glu448, an amino acid with an acidic
side chain, may be a critical site for anchoring positively charged substrates under
physiological conditions. Cys474, which was identified in a prior study as a critical site for
forming a pathway for hOCT2 mediated TEA transport and confirmed through homology
models based on the crystallized structure of LacY [146], was also identified in the
present study for interacting with TPA. This finding was not too surprising considering the
shared quaternary nitrogen-based structural scaffold of TEA and TPA. From these
observations, our model suggests that there may be one binding pocket along the central
cavity of hOCT2. Within this binding pocket, there may be a core set of amino acids that
interact with most substrates, in conjunction with additional substrate-specific amino acids
that accommodate structurally diverse (typically larger) substrates. Additional in vitro work
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involving transporter mutagenesis experiments and subsequent kinetic analysis for each
substrate would be necessary to support the preliminary in silico findings.
Based on the in silico hOCT2 modeling and subsequent in vitro kinetic studies, the
amino acids most critical for MPP+ interactions reside in TMDs 5, 7 and 10. Prior studies
based on secondary and tertiary structures identified critical interacting residues in TMDs
4, 10, and 11 [124,125,143,146,148,153]. There are a number of factors that could
explain this apparent discrepancy. The majority of the prior substrate interaction studies
were done with rodent OCTs; thus, species differences could account for the variations
of identified residues. Additionally, different substrates were examined; TEA and choline
were used in the rat and rabbit studies whereas the focus of the current work was on
interactions with MPP+. As revealed in the analysis of docking diverse substrates in the
current study, critical interacting amino acids may be unique to each substrate. This is not
a surprising result given the diverse array of structures represented by OCT2 substrates.
Finally, for the homology studies that have been performed previously, the templates
utilized (LacY and GlpT) were both crystallized in the inward open conformation.
Considering that PiPT was crystallized in the occluded state, different amino acids may
be exposed to the substrates during in silico docking across the two conformation states.
It may most likely be a combination of the latter two aspects in that structurally diverse
substrates interact with unique sets of amino acids in a “transport channel” and these also
vary as the transporter transitions through outward open, occluded, and inward open
stages during substrate translocation.
In summary, a homology model for hOCT2 based on an existing crystallized
structure of PiPT was successfully generated. Amino acid residues that may be critical
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for hOCT2 transporter-substrate interactions along with a proposed binding pocket region
were identified based on the selected MPP+ docked model and were probed in vitro
through mutagenesis studies. Additionally, a study involving the docking of known
substrates into hOCT2 models identified overlapping and additional residues that may
mediate transporter binding interactions. The results obtained in our combined in silico
and in vitro study suggests a single binding region present along a central cavity within
hOCT2 that shares some similarity with models generated in earlier published work.
Future work, particularly confirming successful membrane targeting of non-functional
hOCT2 mutants, will be necessary to strengthen our conclusions. Despite this
shortcoming, the data acquired in the present study provides a sound foundation for
understanding the physiochemical nature of hOCT2-substrate interactions that may
ultimately serve to help optimize future rational drug design.
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CHAPTER 4

IDENTIFYING STRUCTURAL ELEMENTS OF HUMAN ORGANIC CATION
TRANSPORTER 1 (SLC22A1) MEDIATING SUBSTRATE-TRANSPORTER
INTERACTIONS

4.A

INTRODUCTION
The organic cation transporters (OCTs), OCT1, OCT2, and OCT3, are members

of the solute carrier 22 (SLC22) subfamily of the major facilitator superfamily and via
facilitated diffusion are responsible for the cellular entry of a variety of structurally diverse
small organic molecules typically with positive charge. The OCT paralogs share
similarities in their sequence, transmembrane topology, preferred substrates, and
mechanism of substrate translocation. Despite these similarities, their sites of expression
in the major organ systems vary. In humans, OCT1 and OCT3 both mediate substrate
entry into enterocytes (OCT1 and OCT are expressed along the basolateral membrane
and brush border, respectively) [1]. OCT1 and OCT3 are expressed along the sinusoidal
membrane of hepatocytes in the liver playing a role in the first steps of hepatic elimination
for their substrates [6]. In kidney, OCT2 and OCT3 are expressed on the basolateral
membrane of proximal convoluted tubules governing the initial process of renal
elimination [1]. OCTs have been shown to interact with hundreds of different endogenous
and exogenous substrates/inhibitors under physiological conditions which include
metabolites (e.g. creatine), neurotransmitters (e.g. serotonin, dopamine), hormones (e.g.
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corticosterone), receptor antagonists (e.g. cimetidine), and antidiabetics (e.g. metformin)
[1]. Due to their polyspecific nature and their tissue expression profiles, OCTs play a
pivotal role in the absorption and elimination of their substrates impacting their
pharmacokinetics and efficacy. As such, there is an increased potential for drug-drug
interactions in patients taking concomitant medications.
OCT2, is an important mediator of renal elimination and also a major site for
clinically important drug-drug interactions. In turn, OCT2 has been routinely studied
during the drug development process and is even included in regulatory guidances (e.g.
FDA and EMA) as a protein target for the evaluation of new drug entities as
substrates/inhibitors [112,113]. OCT1, on the other hand, despite being expressed in the
sinusoidal membrane of hepatocytes and potentiating the initial steps of hepatic
elimination for hundreds of compounds, has only recently emerged as a “clinically
important” transporter. Evidence has been reported highlighting the significance of OCT1
in drug-drug interactions and pharmacogenetic variability [116,161,162]. For example,
fenoterol, a widely used narrow therapeutic window anti-asthmatic drug, was shown to
have its pharmacokinetics and pharmacodynamics affected by genetic variants of OCT1
[161]. Compared to healthy individuals, OCT1-deficient patients demonstrated a 1.9-fold
increase in systemic fenoterol exposure and 1.7-fold decrease in volume of distribution.
As a result, heart rate and blood glucose both significantly increased by 1.5-fold, and 3.4fold, respectively [161]. OCT1 also was shown to mediate hepatic uptake of sumatriptan,
a drug used to treat acute migraines [116]. Systemic exposure of sumatriptan was
increased by 2.1-fold in OCT1-deficient patients which was comparable to individuals with
liver impairment. OCT1 polymorphisms, showed similar pharmacokinetic effects for the

89

active metabolite of the opiate analgesic tramadol, tropisetron, where systemic exposure
was increased by 2-fold in homozygous OCT1 variant carriers [162]. These studies
strongly suggest hepatic OCT1 to be a clinically important mediator of pharmacogenetic,
pharmacokinetic and pharmacodynamic variability, and potentially drug-drug interactions.
For the aforementioned studies, OCT1 serves as the rate limiting step for the transfer of
many drugs from the systemic circulation to the liver. As OCT1 governs the hepatic
clearance of these compounds, it essentially serves to mediate systemic drug exposure,
thus establishes itself from a mechanistic DDI perspective as a potential major
determinant of pharmacokinetics and drug clearance [163]. In light of the evidence,
members of the International Transporter Consortium have even raised strong
suggestions that evaluations of OCT1 be included as part of a rational drug design
strategy [163].
Having the 3-D structural information available for hOCT1 is paramount for
obtaining a better understanding of transporter-substrate interactions from a
physicochemical perspective. However, to date, a crystal structure for any SLC22 family
member has yet to be solved. An alternative strategy involves the construction of a
homology model using the known crystal structure of a closely related protein (in this case
transporter). Earlier studies have used the prokaryotic lactose permease (LacY) and
glycerol-3-phosphate (GlpT) transporters as templates for studying the structures of
OCT1 and OCT2 in rat, rabbit, and human [124,127,143,145,146,148] (Table 1.5).
Despite these efforts identifying a number of amino acid residues that may be critical for
OCT-substrate interaction, their models were generated based on templates that were
prokaryotic in origin, crystallized in an inward facing conformation, and shared low OCT
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sequence similarity (~15%). Additionally, the homology models were generated in order
to confirm the spatial orientation of important residues identified in vitro, rather than used
as a preliminary step for guiding amino acid mutational experimentation.
In the current study, the elucidation of critical amino acid residues for transportersubstrate binding interactions of hOCT1 was conducted by the generation of homology
models using the Piriformospora indica phosphate transporter (PiPT), a structurally
related eukaryotic transporter, as template. The information acquired from the newly
constructed model was utilized in order to make predictions and assist in facilitating site
directed mutagenesis studies to assess the homology model’s validity and to observe any
potential changes in transport function and/or affinity (Km) for its prototypical substrate,
MPP+. Docking studies for hOCT1 were performed for additional known substrates with
varying structure in order to more broadly investigate transporter-substrate interaction.
Further defining how OCT1 biochemically interacts with its broad array of substrates will
provide significant insight to the understanding and prediction of drug-drug interactions in
polypharmacy patients and the advancement of future rational drug design for
therapeutics targeting OCT1.
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4.B

MATERIAL AND METHODS

4.B.1 Chemicals and reagents
Tritiated [3H] MPP+ was purchased from PerkinElmer Life and Analytical Science
(Waltham, MA) and unlabeled MPP+ was obtained from Sigma-Aldrich (St. Louis, MO).
Quinine monohydrochloride dihydrate was purchased from Acros Organics (Fair Lawn,
NJ). Bio-Rad protein assay dye reagent concentrate was purchased from Bio-Rad
Laboratories, Inc. (Hercules, CA). Specific primers for mutation reactions were purchased
from Integrated DNA Technologies (IDT; Coralville, IA). QuikChange Lightning SiteDirected Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA).
Lipofectamine® 2000 Transfection Reagent and Prolong diamond antifade mountant with
DAPI was purchased from ThermoFisher Scientific (Waltham, MA). QIAprep spin
miniprep kit and QIAprep spin midiprep kit [154] were purchased from QIAGEN Inc.
(Germantown, MD). GoTaq green master mix was purchased from Promega (Madison,
WI). Opti-Mem reduced serum and Dulbecco’s modified eagle’s medium were purchased
from Life Technologies (Carlsbad, CA).
4.B.2 Homology modeling and docking studies
The hOCT1 (UniProt ID: O15245) and PiPT (PDB ID: 4J05) sequences were
obtained from the Universal Protein Resource (UniProt) and PDB, respectively [131,155].
Protein sequence alignment of PiPT and hOCT1 was performed with ClustalX and
followed by sequence curating via loop removal and manual refinement of gaps based on
the transmembrane domains observed in the PiPT crystal structure and predicted for
hOCT1 using ICM Browser (Molsoft LLC) and Phobius (Stockholm Bioinformatics
Center). Amino acid sequence alignment of hOCT1 with the template and subsequent
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generation of a population of 100 homology models were performed using ClustalX 2.1
and MODELLER v9.17, respectively. Using SYBL-X 2.1, a structural cavity search was
conducted for each model to identify putative binding pocket(s). The hOCT2 substrates,
MPP+, epinephrine, serotonin, cimetidine, tetrapentylammonium (TPA) and metformin,
and the hOCT2 inhibitor, quinine, (Figure 4.1) were sketched and energy-minimized using
SYBL-X 2.1 (Tripos Force Field, Gasteiger-Hückle charges distance-dependent dielectric
constant = 4.0 D/Å) and docked into each of the 100 models within a 15 Å radius of Trp354
(a residue present within the identified binding pocket) using GOLD Suite 5.5. A favorable
model was selected based on the combined MODELLER discrete optimized protein
energy (DOPE) score, GOLD docking score, and Ramachandran plot results. The DOPE
score, accounting for spherical and finite shape of the native structures, helps to
determine the quality of the protein models. The GOLD score evaluates the interactions
of the docked substrate within the proposed binding pocket(s). Ramachandran plots were
used to help visualize energetically allowed regions for backbone dihedral angles against
amino acid residues in the protein structure. A model with more than 90% of amino acids
located in the favorable regions of a Ramachandran plot is generally considered an
acceptable model. High resolution images were obtained using PyMOL v1.8.and SYBLX-2.1.

93

Figure 4.1 Chemical structures of compounds docked into hOCT1 homology
models.
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4.B.3 Bacterial transformation
Plasmid DNA (pcDNA3-hOCT1) was transformed through the following steps:
adding 10 ng of DNA to 50 µL of DH5alpha competent cells, incubating on ice for 30
minutes, and then applying heat shock at 42°C for 20 seconds. The mixture was then
added to 950 µL of 37°C preheated LB broth and incubated while shaking (225 rpm) at
37°C for one hour. Afterward, the mixture was plated onto LB agar plates containing
ampicillin (0.1 mg/mL) and incubated overnight at 37°C. The following day, colonies were
picked and grown overnight (with shaking at 225 rpm) in LB broth with ampicillin
(0.1mg/mL) at 37°C. Plasmid DNA extraction was performed using the Qiaprep spin
miniprep kit according to the manufacturer’s recommendations [154]. Bacterial pellets
were resuspended and lysed, followed by the use of spin columns to isolate plasmid DNA
and wash/discard any impurities in the flow through. Eluted plasmid DNA from the column
was stored at -20°C. Plasmid DNA concentration and purity were determined via UV
spectrophotometry.
4.B.4 Point mutation of plasmid DNA
Synthetic oligonucleotide primers containing the desired DNA mutations were
designed using the QuikChange Primer Design program (Agilent Technologies) (Table
4.1). Amino acid substitutions were introduced into the hOCT1 coding sequence via site
directed mutagenesis (QuikChange Lightning Site-directed Mutagenesis Kit) according to
the manufacturer's recommendations. The resulting mutant plasmids were transformed
into XL 10-GOLD ultra-competent cells according to the manufacturer’s protocol and
plated on LB-agar plates with ampicillin (0.1 mg/mL) and incubated overnight at 37°C.
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Colonies were picked, purified, and the presence of the desired mutation was then
confirmed by DNA sequencing.
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Table 4.1 Primers for hOCT1 site directed mutagenesis.
Protein residue Direction
Mutant oligonucleotide (5' → 3')
Gln241Glu
Forward
CCG TGA AGG CCA TCT CGT ACA TGA TCG CCA C

Gln241Lys

Phe244Tyr

Phe244Ser

Thr245Ser

Thr245Lys

Tyr361Phe

Reverse

GTG GCG ATC ATG TAC GAG ATG GCC TTC ACG G

Forward

CCG TGA AGG CCA TCT TGT ACA TGA TCG CCA C

Reverse

GTG GCG ATC ATG TAC AAG ATG GCC TTC ACG G

Forward

CAG CCC CAC CGT GTA GGC CAT CTG GTA

Reverse

TAC CAG ATG GCC TAC ACG GTG GGG CTG

Forward

CAG CCC CAC CGT GGA GGC CAT CTG GTA

Reverse

TAC CAG ATG GCC TCC ACG GTG GGG CTG

Forward

CCA GCC CCA CCG AGA AGG CCA TCT G

Reverse

CAG ATG GCC TTC TCG GTG GGG CTG G

Forward

CAG CCC CAC CTT GAA GGC CAT CTG GTA CAT

Reverse

ATG TAC CAG ATG GCC TTC AAG GTG GGG CTG

Forward

GAG CCC CTG AAA GAG CAC AGA GTC CGT GA

Reverse

TCA CGG ACT CTG TGC TCT TTC AGG GGC TC
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Tyr361Ala

Gln447Glu

Gln447Lys

Forward

CAC GGA CTC TGT GCT CGC TCA GGG GCT CAT CCT G

Reverse

CAG GAT GAG CCC CTG AGC GAG CAC AGA GTC CGT G

Forward

CAC CAG GCA GAT CAT TTC TAT TGC AAT GGT GAT TCC

Reverse

GGA ATC ACC ATT GCA ATA GAA ATG ATC TGC CTG GTG

Forward

TCA CCA GGC AGA TCA TTT TTA TTG CAA TGG TGA TTC CC

Reverse

GGG AAT CAC CAT TGC AAT AAA AAT GAT CTG CCT GGT GA
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4.B.5 Cell line transfection and maintenance
Mutant transporter expressing CHO cell lines were generated using cationic lipidbased transfection. Briefly, 1μg plasmid DNA was combined with 2 µL Lipofectamine
2000 (Invitrogen), mixed, diluted in 100 µL Opti-MEM (Invitrogen) and applied to CHO
cells at 50-60% confluency in 12-well plates (Corning Inc, Corning, NY). Fresh culture
medium (DMEM/F12) was applied just prior to the addition of transfection agents. After
incubating for 24 hours at 37°C / 5% CO2, the transfection medium was removed and
replaced with fresh medium containing geneticin (G418; 1 mg/mL) to select for
successfully transfected cells for a period of 14-21 days.
CHO control, CHO-hOCT1 and CHO-hOCT1 mutant cell lines were maintained in
Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12) with 10% FBS, and 1%
Penicillin/Streptomycin at 37°C with 5% CO2 in 25 or 75mm 2 polystyrene flasks. G418
(250μg/mL) was included in the medium for maintaining selective pressure on stablytransfected cell lines. Cells were sub-cultured every 3-4 days and passages 10-40 were
used for experiments.
4.B.6 Cell accumulation assays
Mutant functional screening
The procedure for the cell accumulation assay has been described previously
[68,69]. Briefly, cells were seeded into 24-well tissue culture plates at a density of 1.5×10 5
cells/well in the absence of antibiotics and cultured for 48 hours. Cells were equilibrated
with transport buffer for 10 min (500 µL of Hanks’ balanced salt solution containing 10
mM HEPEs, pH 7.4). Equilibration transport buffer was replaced with 400 µL of fresh
transport buffer containing 1 µM unlabeled MPP + spiked with trace [3H]MPP+ (0.25 µCi/ml)
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in the presence or absence of the inhibitor quinine (200 µM). After incubation for 10
minutes, the cells were immediately rinsed 3 times with ice cold transport buffer, lysed
with 200 µL 1N NaOH, neutralized with 250 µL 1N HCl and 200 µL 10mM HEPES. The
radioactivity in cell lysates was quantified by liquid scintillation counting, and uptake
normalized by the total protein content determined by the Bradford method. The
intracellular accumulation of substrates was reported as picomoles of substrate per
milligram total protein. All uptake data were corrected for background accumulation in
corresponding CHO empty vector cells.
Kinetic assays
The Michaelis-Menten constant (Km) was determined for MPP+ uptake in each of
the generated mutant hOCT1-expressing cell lines via saturation analysis according to
our established protocol [156]. The experiment was carried out in the same way as
described for the functional screening assay with the exception that the equilibration
transport buffer was replaced with 400 µL of fresh transporter buffer containing increasing
concentrations (1-200 µM) of unlabeled MPP+ spiked with [3H]MPP+ (0.25 µCi/ml) and
incubated for a period of 1 minute. After incubation, the cells were immediately rinsed 3
times with ice cold transport buffer and lysed with 1N NaOH, neutralized with 250 µL 1N
HCl and 200 µL 20mM HEPES. The Km estimate, which represents the concentration of
substrate at half maximum velocity of the transporter, was calculated using nonlinear
regression with the enzyme kinetics model in GraphPad Prism 5.0 (GraphPad Software
Inc., San Diego, CA). Individual saturation experiments were repeated at least three times
with duplicate wells and plotted as mean ± SD. Km estimates were reported as mean ±
SE.
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4.B.7 Genomic DNA integration confirmation
Cells were suspended in 500 μL lysis buffer [1 M Tris (pH 8.0), 5 M NaCl, 0.5 M
EDTA, and 10% SDS] containing proteinase K (0.4 mg/mL) and incubated at 55°C while
shaking overnight. Genomic DNA was thoroughly extracted from samples with an equal
volume of phenol/chloroform/isoamyl alcohol (25:24:1) after gentle mixing for 10 min, and
centrifugation for 10 min at 15,000 g. The upper aqueous phase was carefully collected,
isopropanol was added and mixed well, then centrifuged immediately at 15,000 g for 30
min to obtain DNA pellet. The pellet was washed with 70% ethanol, dried, and
resuspended with 50 µL TE buffer [10 mM Tris (pH 8.0), and 1 mM EDTA]. Concentration
of DNA was determined through UV spectrophotometry. Genomic DNA (2 ng), 2x Go-taq
Master Mix (5 μL), as well as 1 μL primer pair mix (T7: 5’- TAATACGACTCACTATAGGG3; hOCT1-REV: 5’- TGAAGGCCATCTGGTACATG -3’) were added together to a final
volume of 20 µL and run in a thermocycler: initial denaturation at 95°C for 5 min, followed
by 30 cycles of: denaturation at 95°C for 2 min, annealing at 50-52°C for 30 seconds, and
elongation at 72°C for 30 seconds. Final elongation step at 72°C for 5 min and held at
4°C. PCR products were loaded into a 1% agarose gel for separation using
electrophoresis at 120 V for 60 min and visualized by UV light following ethidium bromide
staining.
4.B.8 Green fluorescent protein (GFP) plasmid construction
To make the hOCT1-GFP fusion construct, the full length hOCT1 cDNA fragment
was removed from the isolated library clone, pcDNA3/hOCT1, using the restriction
enzymes Kpn I and Xba I. The fragment was gel isolated and ligated into the pEGFP-C1
vector in frame at the carboxyl terminal end of GFP forming the plasmid pEGFP-
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C1/hOCT1, where “E” denotes “enhanced”. Plasmid construction was performed
commercially (GenScript, Picataway, NJ). The lyophilized GFP plasmid construct, was
resuspended and diluted in TE pH 8, transformed into DH5-alpha cells and DNA extracted
using the Qiagen miniprep kit. The construct was confirmed by DNA sequencing. Nonfunctional hOCT1 mutants were reproduced in the hOCT1-GFP construct using the
original primers (Table 4.1) and the QuikChange Lightning site-directed mutagenesis kit.
4.B.9 Microscopic imaging
An Olympus IX-70 inverted microscope fit with a 12-bit camera was used to
capture phase contrast and fluorescent images (Olympus, Melville, NY). Fluorescent
images were taken with two second exposures using a 595 nm dichroic long pass filter
(Chroma, Rockingham, VT) illuminated by a mercury arc lamp. The images were
processed using Olympus Microsuite v.5. Confocal fluorescent images were obtained at
the VCU Microscope Core facility using a Zeiss LSM 710 Axio Observer inverted laser
scanning confocal microscope fitted with a 63x oil immersion objective. Images were
collected by illuminating samples with a blue diode laser at 405 nm. Images were
processed using Zeiss ZEN 2 Blue edition software (Oberkochen, Germany).
4.B.10 Statistics
The data plots were presented as means ± SD. Dose response curve (Km estimate)
data were reported as mean ± SE for at least n = 3. Km estimates were fit based on the
equation: V0 = Vmax * [S] / (Km + [S]). One-way ANOVA with post-hoc Dunnett’s test was
used to evaluate differences compared to a single control where indicated. Statistical
calculations were performed using Prism 5.0 (GraphPad Software, Inc., San Diego, CA).
A difference was deemed statistically significant if p < 0.05.
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4.C

RESULTS

4.C.1 Identification of a hOCT1 model
The hOCT1 peptide sequence (Uniprot ID: O15245) was aligned with the PiPT
template sequence (PDB ID: 4J05) (Figure 4.2) as input for the program MODELLER to
generate 100 initial hOCT1 homology models. Analysis of the initial 100 models identified
a single large cavity in the central region of the transporter as a potential binding pocket.
MPP+ was subsequently docked in this region. After docking MPP + into the generated
hOCT1 models, the most favorable interaction model was selected based on three main
criteria: GOLD docking score, DOPE score, and the total number of clusters.
The genetic optimized ligand docking (GOLD) scoring is essentially a method to
quantify which poses generated for a particular ligand are most likely to occur based on
the interactions present within the transporter. GOLD scores for the top ten most
favorable docked poses of MPP+ in the binding pocket of the hOCT1 models (ranging
from 58.52 to 64.5) were ranked (Table 4.2). Amongst this select group, the top four
model’s GOLD scores had a difference of 1.85 between them, thus were considered to
be virtually identical. The difference between the top and fifth ranked model was
increasingly larger (2.72). The discrete optimized protein energy (DOPE) score accounts
for the shape of native structures which in turn helps to evaluate the quality of the whole
protein structure. The DOPE scores for the top ten models ranged between -48,992 and
-47,382 (Table 4.2). Additionally, the number of homology models which contained a
given substrate pose (number of clusters) was also accounted for in model selection. The
greater the number of models that have a particular substrate pose docked, the higher
the likelihood that the specific pose occurs within the binding pocket. Out of the top 10
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models, models 35 and 47 had the highest number of clusters (12 and 8 clusters,
respectively), while the rest had 5 or less. Among the top four ranked GOLD score
models, model 35 stood out as having the lowest DOPE score (-48,141; fifth lowest DOPE
score overall) in conjunction with the highest number of clusters (12). Taken together,
these three selection criteria indicate model 35 as the most favorable docked model and
thus it was selected for subsequent studies. The generated tertiary structure for model 35
with MPP+ docked in the hypothesized binding pocket is shown in Figure 4.3. The docked
hOCT1 model shows MPP+ residing inside a large central cavity of the 12-membrane
spanning alpha helical domains.
Ramachandran plots were utilized as a method for determining and visualizing
“allowed regions” for the backbone dihedral angles that make up amino acids in the
generated model. For the amino acids that made up our selected hOCT1 model, 90.0%
were in the most favored regions, 7.3% were in the additionally allowed region, and only
2.7% were in the generously allowed and disallowed regions combined (Figure 4.4). The
most favored regions category was considered high enough to support the selected
hOCT1 model as acceptable.
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Figure 4.2 Sequence alignment of PiPT and hOCT1.
The alignment was constructed with ClustalX, followed by manually refining gaps based
on the transmembrane regions observed in the PiPT crystal structure and predicted for
hOCT1 using Phobius, a topology prediction algorithm. Residues were truncated for the
large extracellular and intracellular loop between transmembrane domain 1 and 2 (TMD
1 and 2) and between TMD 6 and 7 of PiPT and hOCT1, respectively. The
transmembrane domains in the hOCT1 model and PiPT tertiary structure are shaded. “*”
indicates exact sequence match, “:” indicates high sequence similarity, “.” indicates low
sequence similarity
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Table 4.2 Summary of hOCT1 model evaluation scores.
GOLD Rank
1

Model ID
93

GOLD score
64.5

DOPE Score
-47779.43359

No. of
Clusters
5

2

22

63.65

-47533.55859

1

3

35

63.07

-48141.65625

12

4

100

62.65

-48001.56641

3

5

91

61.78

-48538.58984

3

6

47

60.58

-48042.83594

8

7

85

60.31

-47898.90625

1

8

46

60.21

-48336.22656

2

9

80

58.99

-47382.37891

1

10

73

58.85

-48217.75

2
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Figure 4.3 hOCT1 homology model.
The generated 3-D molecular structure of hOCT1 (ribbons) is shown with MPP+ (space-filled) positioned in the putative
binding pocket viewed from (A) profile and (B) top-down angles.
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Figure 4.4 Ramachandran plot for hOCT1 homology model.
Phi and psi indicate backbone conformation dihedral angles of amino acid residues,
representing the rotations of a polypeptide main chain N-Cα and Cα-C bonds. Amino
acids are displayed in different regions: most favored region (red), additional allowed
region (yellow), generously allowed region (light yellow), and disallowed region (white).
Residues depicted in red squares are in the generously allowed and disallowed regions.
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4.C.2 Identifying amino acid residues important for MPP + hOCT1 interaction
Several amino acids were identified that made up the binding pocket (within the
designated 5 Å radius of the substrate) for docked MPP+ in the selected hOCT1 model.
The identified amino acid residues were found in several different TMDs that came
together in the central area forming a large distinct cavity of the transporter—TMD 1:
Trp16; TMD 5: Ile238, Gln241, Met242, Phe244, Thr245, Val246; TMD 7: Trp354,
Asp357, Ser358, Tyr361, Gln362; TMD 8: Glu386, Ile387, Ala390; TMD 10: Ile444,
Gln447, Ile449, Cys473 (Figure 4.5). Within the proposed binding pocket, five amino acids
were identified (Gln241, Thr245, Phe244, Tyr361, and Gln447) as potential candidates
critical for transporter-MPP+ binding interactions. Hydrophobic interactions were found
between MPP+ and amino acid residues Gln241, Thr245, and Glu447, and one of the
aromatic rings of MPP+ was recognized as forming edge-face-pi and pi-stacking
interactions with Phe244 and Tyr361, respectively (Figure 4.6 and Table 4.3).
To further evaluate the generated in silico hOCT1 model, known substrates with
disparate structures were optimized and docked into the population of 100 models to
determine the presence of alternative and/or additional critical amino acid residues in the
binding pocket(s). The process involved with selecting the most favorable model for
MPP+, was repeated for each docked substrate. Amino acids identified with the greatest
overlap across the different docked compounds were Phe244, Asp357, Tyr361, and
Gln447 (Figure 4.7 and Table 4.3). There were several amino acids identified that were
also unique to particular compounds including Thr245 for MPP +; Trp16, Asn156, Phe159,
and Asp474 for cimetidine; Gln20 for epinephrine; Leu23 for quinine; Ser358 for
serotonin; and Ile449 for TPA.

109

Figure 4.5 3-D rendering of putative binding pocket of hOCT1 with docked MPP+.
Amino acid side chains (white) comprising the binding pocket surrounding the substrate MPP+ (orange) is shown viewed
from (A) profile and (B) top-down angles.
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Figure 4.6 Structure of hOCT1 with MPP + docked.
The docked substrate (MPP+, orange) and the amino acids (white side chains) is shown
localized in the predicted substrate binding pocket of hOCT1.
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Table 4.3 hOCT1 docking interaction summary.
Sequence
Substrate
Amino Acid
Bond Interaction
position
MPP+
Gln
241
Hydrophobic

Cimetidine

Epinephrine

Metformin

TMD
5

Phe

244

Edge Face pi

5

Thr

245

Hydrophobic

5

Tyr

361

Pi-stack

7

Gln

447

Hydrophobic

10

Trp

16

Hydrophobic

1

Asn

156

H-bond

2

Phe

159

Pi-stacking

2

Trp

217

Hydrophobic

4

Phe

244

Hydrophobic

5

Asp

357

H-bond (salt bridge)

7

Tyr

361

Pi-stacking

7

Gln

362

H-bond

7

Asp

474

H-bond (salt bridge)

11

Gln

20

H-bond

1

Phe

244

Edge-face pi

5

Asp

357

H-bond

7

Tyr

361

Pi-stacking

7

Gln

447

Hydrophobic

10

Cys

450

Hydrophobic

10

Phe

244

Edge-face pi

5
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Quinine

Serotonin

TPA

Trp

354

Hydrophobic

7

Asp

357

H-bond (salt bridge)

7

Tyr

361

Pi-stack

7

Gln

447

Hydrophobic

10

Cys

473

Hydrophobic

10

Leu

23

Hydrophobic

1

Trp

217

Hydrophobic (weak)

4

Phe

244

Hydrophobic

5

Asp

357

H-bond

7

Tyr

361

Pi-stacking

7

Gln

447

H-bond

10

Cys

473

Hydrophobic

10

Gln

241

H-bond

5

Phe

244

Hydrophobic

5

Asp

357

H-bond

7

Ser

358

Hydrophobic

7

Tyr

361

Pi-stack

7

Gln

362

H-bond

7

Ile

444

Hydrophobic

10

Cys

473

H-bond

10

Phe

244

Hydrophobic

5

Asp

357

Ionic w/quaternary N

7

Tyr

361

Hydrophobic

7

113

Ile

444

Hydrophobic

10

Gln

447

Hydrophobic

10

Ile

449

Hydrophobic

10

Cys

450

Hydrophobic

10
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Figure 4.7 Known hOCT1 substrates docked into hOCT1 homology model.
Known hOCT1 substrates (purple or orange) (A) cimetidine, (B) epinephrine, (C) metformin, (D) quinine, (E) serotonin, and
(F) TPA, were docked into their respective favorable hOCT1 models. Proposed interactions of interactions are summarized
in Table 4.3.
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4.C.3 Substitution of hOCT1 amino acid residues in putative binding pocket
We investigated the role of the predicted amino acids in hOCT1-MPP+ interactions
through conservative and non-conservative amino acid substitutions introduced into the
hOCT1 coding sequence to evaluate potential changes in hOCT1 function and affinity for
MPP+. The pcDNA3/hOCT1 plasmid vector map is shown in Figure 4.8. The rationale for
deciding each conservative and non-conservative amino acid substitution was based on
a scheme developed by Bordo et al. which categorizes roughly equivalent amino acid
residues based on their physicochemical properties of their side chains (Figure 4.9) [157].
Substitutions for residues deemed critical were Gln241Glu, Phe244Tyr, Thr245Ser,
Tyr361Phe, and Gln447Glu (conservative); and Gln241Lys, Phe244Ser, Thr245Lys,
Tyr361Ala, and Gln447Lys (non-conservative) (Tables 4.4, 4.5, and 4.6). Several
attempts were made to generate the hOCT1 Tyr361Phe mutant. However, each time, the
desired mutation was present as a tandem repeat, i.e., the entire target region
incorporated into the mutation generating primers was duplicated in the final product. We
were unable to resolve how or why this occurred. All successfully constructed hOCT1
mutants were confirmed by DNA sequencing prior to generating stable cell lines. Figure
4.10,

depicts

a

representative

DNA-oligonucleotide

duplex

and

sequencing

chromatogram in which CAA, coding for Gln447 in wildtype hOCT1, was changed to GAA,
coding for the hOCT1 mutant Gln447Glu.
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Figure 4.8 pcDNA3/hOCT1 vector map.
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Figure 4.9 Suggested guidance for amino acid residue conservative substitution.
Roughly equivalent amino acid residues categorized based on physiochemical properties into five subgroups.
Diagram is an adapted figure from reference [157]
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Table 4.4 Summary of hOCT1 residue substitutions.
Substitution
Residue

a

Conservative

Non-Conservative

Gln241

Glu

Lys

Phe244

Tyr

Ser

Thr245

Ser

Lys

Tyr361

Phea

Ala

Gln447

Glu

Lys

Mutant was not able to be generated
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Table 4.5 hOCT1-MPP+ interaction based conservative substitutions.
Sequence
Amino Acid
Codon
Mutant Codon
Substitution
position
Gln
241
CAG
GAG
Gln → Glu
Phe

244

TTC

TAC

Phe →Tyr

Thr

245

ACG

TCG

Thr → Ser

Tyr

361

TAT

TTT

Tyr → Phea

Gln

447

CAA

GAA

Gln → Glu

a mutant

was not able to be generated
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Table 4.6 hOCT1-MPP+ interaction based non-conservative substitutions.
Sequence
Amino Acid
Codon
Mutant Codon
Substitution
position
Gln
241
CAG
AAG
Gln → Lys
Phe

244

TTC

TCC

Phe →Ser

Thr

245

ACG

AAG

Thr →Lys

Tyr

361

TAT

GCT

Tyr → Ala

Gln

447

CAA

AAA

Gln → Lys
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Figure 4.10 Representative sequencing chromatogram for hOCT1 mutants.
(A) DNA template-primer duplex for hOCT1 Q447E. Chromatogram for (B) hOCT1
wildtype and (C) hOCT1 Q447E are shown with triplet codon corresponding to mutation
site highlighted
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4.C.4 Critical amino acid confirmation through kinetic assays
In functional screening assays evaluating [3H] MPP+ transport (Figure 4.11), wildtype hOCT1 demonstrated a 5-fold higher uptake of MPP + compared to mock expressing
(pcDNA3) background control cells (11.7 ± 4.9 pmol mg protein-1 10 min-1 vs. 2.4 ± 0.02
pmol mg protein-1 10 min-1). Quinine (200 µM), a known inhibitor for OCTs, virtually
abolished hOCT1 mediated MPP+ transport. Four non-conservative mutants, hOCT1
Glu241Lys, Thr245Lys, Tyr361Ala, and Gln447Lys, resulted in a complete loss of MPP +
transport activity (Figure 4.11). All other mutants retained some level of transport activity
and were subjected to saturation analysis in order to estimate Km (Figure 4.12, Table 4.7).
The affinity of MPP+ determined for wildtype hOCT1 was comparable to values in
prior studies (Km = 16.3 ± 3) [158]. When comparing the Km estimates for hOCT1 mutants
against wildtype hOCT1, the non-conservative substitution Phe244Ser and the
conservative substitution Thr245Ser resulted in a significant decrease in affinity for MPP +.
The mutants Gln241Glu, Phe244Tyr, and Gln447Glu, all demonstrated no significant
change in affinity for MPP+.
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Figure 4.11 Functional screen of CHO-hOCT1 wild type and mutant expressing cell
lines.
CHO cells were treated with transport buffer containing 1 µM [ 3H] MPP+ (0.25 µCi/mL) in
the absence or presence of inhibitor (quinine) for 10 min. Conservative and nonconservative mutations appear above original amino acid position. Data shown as
duplicate values ± SD. ** denotes p<0.01; *** denotes p<0.001; compared against wild
type control by one-way ANOVA followed by post-hoc Dunnett’s t-test.
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Figure 4.12 Representative dose response curves for wild type and mutant hOCT1.
Michaelis-Menten kinetics of [3H] MPP+ transport (1–200 µM) for hOCT1 and hOCT1
mutants in stably transfected CHO cells.
.
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Table 4.7 Summary of Km estimates for hOCT1 constructs.
hOCT1 Transporter
WT

Km (µM)
16.3 ± 2.5

Gln241Glu

18.2 ± 1.2

Phe244Tyr

24 ± 0.32

Phe244Ser

33.4 ± 5*

Thr245Ser

37.4 ± 6.4*

Gln447Glu

14.3 ± 2.6

Mean Km estimates acquired from triplicate experiments ± SE.
* denotes p < 0.05 compared against wild type control by one-way
ANOVA followed by post-hoc Dunnett’s t-test.
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4.C.5 Genomic integration of non-functional hOCT1 mutant constructs
To eliminate failed genomic DNA integration as an explanation for the lack of
transport activity in non-functional hOCT1 mutants, genomic DNA was extracted and PCR
amplified using the primers T7 and hOCT1 REV, that flanked 5’ and 3’ ends of the hOCT1
coding sequence of the pcDNA3 plasmid (hOCT1 amplicon ~1.7 kb). PCR products of
the expected size (~1.7 kb) were obtained for wildtype hOCT1 and all hOCT1 mutants
(Gln241Lys, Tyr361Ala, Thr245Lys, and Gln447Lys), while no product was observed for
negative controls (water and pcDNA3) demonstrating that all hOCT1 plasmids had been
successfully integrated (Figure 4.13).
4.C.6 Membrane targeting of hOCT1-GFP fusion construct
The full length hOCT1 cDNA fragment was gel isolated and ligated into vector
pEGFP-C1 forming the plasmid pEGFP-C1/hOCT1 containing hOCT1 fused in frame to
the carboxyl terminal of GFP (Figure 4.14). CHO cells expressing the hOCT1-GFP
fusion construct showed strong fluorescence within the cytosol and lack of signal in the
nucleus (Figure 4.15). This pattern is consistent with an intact GFP fusion construct
versus expression of “free” GFP. However, no noticeable fluorescence at the plasma
membrane was observed. Control transfections (lipofectamine only) showed no
fluorescent signal (data not shown). In order to have a reference of the membrane
localization of OCTs, MDCK cells stably transfected with a rat Oct2-GFP fusion
construct from a previous study were grown and observed [159] (Figure 4.16).
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Figure 4.13 PCR analysis of genomic DNA isolated from hOCT1 cell lines.
Confirmation of successful genomic integration of mutant hOCT2 constructs that lacked
transport activity. Lanes: (1) water, (2) pcDNA3, (3) hOCT1, (4) hOCT1 Gln241Lys, (5)
hOCT1 Thr245Lys, (6) hOCT1 Tyr361Ala, (7) hOCT1 Gln447Lys
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Figure 4.14 pEGFP-C1/hOCT1 fusion protein vector map.
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Figure 4.15 Expression patterns of pEGFP-C1/hOCT1.
CHO cells transfected with pEGFP-C1/hOCT1 were fixed, permeabilized, and mounted
at 24 hours post transfection then viewed under confocal microscopy: (A) phase contrast,
(B) GFP, (C) DAPI, and (D) merge. Scale bar = 20 µm
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Figure 4.16 Expression of pEGFP-C3/rOct2 in MDCK cells.
MDCK cells stably transfected with pEGFP-C3/rOct2 were thawed, grown in culture for
48 hours, then observed by fluorescence microscopy (40x magnification). Observed cells
were used in a study performed in reference [159]
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4.D

DISCUSSION
The polyspecific nature of the OCTs make them prime targets for potentially

unwarranted effects of drug-drug interactions. Any insight on the physiochemical nature
of the substrate interactions for these transporters will undoubtedly serve to guide the
prediction of such occurrences. The importance of understanding OCT-substrate
interactions has recently garnered more attention. Several important studies have
identified probable residues for OCT substrate interaction through the use of homology
models based on the crystallized structures of the prokaryotic MFS transporters LacY or
GlpT [143,146,148,153]. Their initial findings were helpful in establishing the usefulness
of this relatively novel technique for the understanding of OCT transport, however, may
be limited due to low sequence identities shared between the templates used and
mammalian OCTs (~15%).
Therefore, in the current study, homology models of the tertiary structure of hOCT1
were generated using the known crystal structure of PiPT serving as the template. PiPT,
also a member of the MFS, was chosen as the designated template due to a number of
factors including its relative sequence homology to the hOCTs (~21% identical, 40%
similar), eukaryotic origin (Piriformospora indica), and the fact that it was crystallized in
the occluded state. The occluded conformation grants the transporter maximum binding
interaction sites for bound ligands. After docking MPP + into the generated hOCT1 models,
amino acid residues were identified that formed the putative binding pocket (within a 5 Å
radius surrounding the substrate) (Figure 4.6). This approach required that several
assumptions be made during the in silico model building process including that adequate
structural similarity exists between the crystallized tertiary structure of PiPT and hOCT1
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and that the presence of water molecules in the occluded binding pocket was negligible
and therefore not considered during the docking analysis. All models were generated
based on PiPT and the hOCT1 protein sequence with transmembrane domains globally
energy minimized. Amino acid residues deemed “critical” for hOCT1-MPP + binding
interactions were identified in silico based on substrate proximity and interaction type
(Table 4.3).
Within the proposed binding pocket, hydrophobic interactions were identified
between MPP+ and amino acid residues Gln241, Thr245, and Glu447, and one of the
aromatic rings of MPP+ was found to be involved in edge-face pi and pi-stacking
interactions with Phe244 and Tyr361, respectively. Subsequently, stably transfected CHO
cells expressing hOCT1 mutants were established and utilized for a series of in vitro
kinetic assays to confirm their role in substrate binding. From the functional screening
study, transport activity of MPP+ was absent in the non-conservative substitution of
Gln241, Thr245, Tyr361, and Gln447 (Figure 4.11). All conservative substituted mutants,
and one non-conservative substitution retained transport function (Phe244). The MPP +
docked hOCT1 model predicted strong interactions for Phe244 and Tyr361 (edge-face pi
and pi-pi stacking, respectively). The retained transport function for both mutants of
Phe244 contradicted the model’s prediction. Loss of transport function by the
conservative Tyr361Ala mutation suggested that this residue may be a critical site for
substrate binding. This result correlates with the MPP + docking data where Tyr361 was
predicted to participate in the strongest substrate interactions (pi-pi stacking). However,
in contrast to hOCT2, we were unable to isolate the conservative hOCT1 Tyr361Phe
mutant. Thus, whether or not a similar possibility as observed for hOCT2 exists for hOCT1
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for the aromatic hydroxyl group to mediate additional important interactions with other
residues within the binding pocket beyond pi-pi stacking with MPP + and, thus, playing a
significant role in forming the structure of the binding pocket, is unknown. Evaluating the
transport function for the conservative substituted mutant of Tyr361 (mutant was unable
to be constructed) would provide stronger support as a critical residue for MPP +
interaction.

For hOCT1 mutants retaining MPP + transport function, Phe244Ser and

Thr245Ser displayed significantly decreased substrate affinity (Table 4.7). In turn, it is
plausible to suggest that Phe244Ser and Thr245Ser are important sites for MPP +
interaction. Future studies involving the generation of a Phe244Ser/Thr245Ser double
mutant could provide additional evidence to support their importance for substrate
interaction. These preliminary findings suggest that Glu241, Phe244, Thr245, Tyr361, and
Gln447 are the leading candidate residues that may be involved in hOCT1-MPP +
interactions. Among these, Thr245 holds the strongest case since its conservative
substituted mutant had significantly attenuated affinity and its non-conservative mutant
demonstrated a complete loss of activity for the transport of MPP +.
The complete loss of MPP+ transport activity by hOCT1 mutants (Gln241Lys,
Thr245Lys, Tyr361Ala, and GLn447Lys) may be due to several of the following factors.
The amino acid could be largely responsible for MPP + interactions such that when
mutated will lead to the loss of transport and/or a change in the overall conformation of
the binding pocket. Alternatively, there could have been issues during the transfection
process leading to the absence of cDNA integration into the genome. Another possibility
is that the amino acid may be critical for the structural integrity or trafficking of the
transporter within the cell. If this were the case, mutations at this residue could lead to
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protein misfolding that is subsequently degraded rather than integrating into the cellular
membrane following its translation.
Genomic integration of intact cDNA for hOCT1 mutants was confirmed by PCR
and gel electrophoresis (Figure 4.13) thus ruling out failed transfection. In order to confirm
that inactive mutant hOCT1 transporters were translated and inserted into the plasma
membranes of transfected mammalian cell lines, a hOCT1-GFP fusion construct was
made by fusing the coding sequence of hOCT1 to the C-terminus of GFP and transfected
into CHO cells. Plasma membrane targeting was achieved in earlier studies using a
similarly constructed GFP fusion construct for rat Oat1 and rat Oct2 transfected into
MDCK cells [159,160]. In the current study, however, plasma membrane targeting was
not observed in CHO cells transiently transfected with the wildtype hOCT1-GFP fusion
construct. Instead a consistent pattern of fluorescence in the cytosol was noticed. The
discrepancy in what was observed compared to the prior studies perhaps may be due to
differences associated with the cell line used (MDCK vs CHO cells). A future study
involving the transfection of our pEGFP-hOCT1 fusion construct into MDCK cells should
be considered.
For the analysis of docking known substrates with a diverse array of structural
features into hOCT1 homology models, amino acids identified were unique to some
substrates and shared for others (Table 4.3). For example, Glu 447 was among the group
of residues that was shared across a diverse group of substrates which included MPP +,
epinephrine, metformin, quinine, and TPA. The conserved residue in rabbit Oct2 (also at
position 447) was identified as a critical site for mediating TEA transport which was
subsequently confirmed in a rabbit Oct2 homology model on GlpT [153]. Under
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physiological conditions, the acidic side chain present in Glu477 may be anchoring the
transport of positively charged compounds. Cys451, identified in a previous study as a
residue important for mediating choline transport by rabbit Oct1 and verified through
homology models based on the solved structure of LacY [144], was also identified in the
present study (Cys450) for interacting with epinephrine and TPA. This observation is
consistent chemically since both choline and TPA both contain a quaternary amine. TPA
was also predicted to interact with Cys473 in the hOCT1 homology model in the current
study. In a different study, the conserved residue, Cys474, in hOCT2 was demonstrated
to mediate TEA transport and verified by a hOCT2 homology model generated based on
the crystallized tertiary structure of GlpT [146]. Both TEA and TPA also share a similar
quaternary nitrogen backbone in their chemical structures which may explain their shared
interaction with cysteine in this particular binding region in hOCT transporters. From these
observations, our model suggests that there may be one binding pocket along the central
cavity of hOCT1. Within this binding pocket, there may be a core set of amino acids that
interact with most substrates, in conjunction with additional substrate-specific amino acids
that that accommodate structurally diverse substrates. Additional in vitro work involving
transporter mutagenesis experiments and subsequent kinetic analysis for each substrate
would be necessary to support the preliminary in silico findings.
From the in silico hOCT1 modeling and subsequent in vitro kinetic work in the
current study, TMDs 5, 7, and 10 were the regions that contained the amino acids
predicted to interact with MPP+. Other OCT-substrate interaction studies identified
important residues in TMDs 4, 10, and 11 [124,125,143,146,148,153]. Several factors
should be considered that could help delineate these apparent disparate observations.
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OCT models generated from different species of rodents were evaluated in the earlier
interaction studies, thus species differences could account for the variations of identified
residues. Interaction studies were conducted on different substrates. The current work
generated hOCT1 models which were docked with MPP +, while the other studies on rat
and rabbit docked TEA and choline. As determined in the analysis involving docking
known hOCT1 substrates, amino acid residues critical for interaction may be unique to
each compound. Given the diverse substrate specificity of hOCT1, this result was not
unexpected. In prior homology model studies, rodent Oct1 was modeled based on the
tertiary structures of LacY and GlpT. The differences in observations may have been
anticipated since the models constructed in the present study were generated by PiPT, a
transporter with higher sequence identity with the mammalian OCTs. And finally, there is
the fact LacY and GlpT were crystallized in the inward conformation which differs from
the occluded state structure solved for PiPT. As such, amino acids that are accessible to
interacting substrates during the in silico docking steps may vary.
In summary, a homology model for hOCT1 based on the solved structure of PiPT
was successfully constructed. Through the docking of MPP + into the generated homology
models, important residues associated with substrate binding interactions as well as the
putative binding pocket were identified. Identified amino acids were further investigated
in subsequent in vitro mutagenesis studies and kinetic analysis. The findings of the
current study suggest that many substrates share both overlapping and unique interaction
sites. Although differences in the identified important residues were recognized through
comparisons with other similar studies, there were a few that were shared. Future work,
particularly confirming successful targeting of the membrane for non-functional hOCT1
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mutants, will be required to strengthen the current claims. Findings from the current study
certainly lays down the foundation for future work that could ultimately offer important
direction for optimizing drug design as well as mitigating the rates of OCT related drugdrug interactions.
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CHAPTER 5

COMPARISON OF SUBSTRATE BINDING INTERACTIONS BETWEEN HUMAN
ORGANIC CATION TRANSPORTERS 1, 2, AND 3

In human, organic cation transporters play a critical role in mediating the transport
of a vast array of endogenous and exogenous compounds across barrier epithelia of the
major distribution and eliminating organ systems; namely the intestine, liver, and kidney
[1]. As such, OCTs, in particular OCT1, 2, and 3, have garnered additional attention from
investigators hoping to better understand their roles in drug disposition and elimination.
To date, due to the lack of a solved crystal structure, very little is known about the threedimensional structure of human OCTs or substrate/protein interactions involved in their
transport. Some early efforts involving the use of secondary structure information to
determine important binding sites of the rat Oct1 and 2 have been conducted [124,125].
Since then, newer strategies involving computational homology modeling have been
conducted to assist in forming more robust predictions as well as helping guide
mutagenesis experiments [128,132]. In the current study, potentially critical amino acid
residues important for transporter-substrate interactions were identified for human OCT1
and OCT2 through in silico molecular modeling techniques, paired with in vitro
mutagenesis and kinetic transporter experiments.
Tertiary homology models for hOCT1 and hOCT2 were successfully generated
using the recently crystallized MFS transporter, PiPT, as template. The generated models
were in silico docked with the prototypical OCT substrate MPP +. The most favorable
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docked MPP+ model was selected based on a series of computational validation methods
and subsequently used to predict several potentially important sites for substratetransporter interaction. This information was used to guide in vitro mutagenesis studies
and kinetic experiments. This experimental strategy was carefully implemented for the
elucidation of residues in both hOCT1 and hOCT2.
From the results obtained from the functional screening assay, four nonconservative mutations of hOCT1 (Glu241Lys, Thr245Lys, Tyr361Ala, and Gln447Lys)
resulted in a complete loss of MPP+ transport activity (Figure 4.11). For hOCT2, this was
the case for two non-conservative mutants, hOCT2 Glu242Lys and Tyr362Ala, and one
conservative mutant hOCT2 Tyr362Phe (Figure 3.11). In a different study conducted in
hOCT3, two conservative mutants, (Trp358Phe and Asp475Glu) and two nonconservative mutants (Val40Ala and Trp358Ala) demonstrated a loss of MPP + transport
activity [164]. Across OCT1-3, the only residue overlap for these sets of experiments was
observed for hOCT1 and hOCT2 (Tyr361/Tyr362 and Gln241/Gln242). The Tyr residue
at these positions in particular were both predicted to participate in the strongest
interactions with MPP+ in their respective homology models (pi-pi stacking) which
correlates with this functional result acquired in vitro. Alternatively, the loss of MPP+
transport activity for the conservative hOCT2 mutant, Tyr362Phe, suggests that the
hydroxyl group in Tyr362 may be interacting with other residues and thus could be a major
contributor to the tertiary structure of the binding pocket. Similar observations were not
able to be made at the conserved site in hOCT1 (Tyr361) since the generation of the
Tyr361Phe mutant was unsuccessful. The most critically involved amino acid in hOCT3MPP+ interactions was Trp358, where both conservative and non-conservative
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substitutions yielded a loss of substrate transport [164]. Taken together, these results
suggest that hOCT1 and hOCT2 share a similar binding pocket with one another,
whereas, the binding pocket for hOCT3 appears unique.
For mutants that retained transport activity, saturation analysis was conducted to
evaluate potential changes in transporter affinity for MPP +. When compared with wildtype
(Km = 16.3 ± 2.5), hOCT1 mutants that were observed to have a significant decrease in
transporter affinity was the non-conservative substitution Phe244Ser and the
conservative substitution Thr245Ser (Km = 33.4 ± 5 and 37.4 ± 6.4, respectively) (Table
4.7). In hOCT2, only the non-conservative substitution Tyr245Ala resulted in a significant
change in affinity for MPP+ (Km = 36.5 ± 5) (Table 3.7). In hOCT3, the conservative mutant
Val40Leu and non-conservative mutants Phe36Ala, Glu451Ala, and the double mutant
Val40Leu/Glu451Ala showed a significant change in substrate affinity [164]. The double
mutant in hOCT3 confirmed Val40 and Glu451 importance in binding interactions since
the affinity was lowered significantly more when both mutations were changed compared
to each mutant changed individually.
The homology models for hOCT1, 2, and 3 were further evaluated by docking
known substrates with disparate structures into each population of 100 models to
determine the presence of alternative and/or additional critical amino acid residues in the
binding pocket(s). Epinephrine, metformin, serotonin, and TPA were docked into all three
OCT models. Additional compounds, cimetidine and quinine, were docked into hOCT1
and hOCT2. Several amino acids, which made up the “core binding residues” based on
their high frequency of overlap across the different docked compounds for each
transporter were identified: hOCT1: Phe244, Asp357, Tyr361, and GLn447 (Table 5.1);
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hOCT2: Tyr245, Ser358, Tyr362, and Glu448 (Table 5.2); and hOCT3: Val40, Met248,
Trp358, and Asp478 (Table 5.3). Amongst this list across hOCT1-3, aspartic acids and
glutamic acids, particularly in TMDs 10 and 11, seem to be important for substrate
interactions. These amino acids with acidic side chains, under physiologic conditions (pH
7.4) are likely to anchor cations as they translocate across the membrane through the
transporter.
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Table 5.1 hOCT1 substrate docking summarya.
Residue
MPP+ Cimetidine Epinephrine Metformin
Trp16
x
Gln20

Quinine

x

Asn156

x

Phe159

x

Trp217

x

Gln241

x

Phe244

x

Thr245

x

x
x

x

x

x

Trp354

x

x

x

x

x

x

x

Asp357

x

x

x

Ser358

x
x

Gln362

x

x

x

x

x

x

x
x

x

x

x

x

Cys450

x

x

Cys473

a

x
x

Ile449

Asp474

x

x

Ile444
Gln447

TPA

x

Leu23

Tyr361

5-HT

x
x

Data acquired from Figure 4.7 and Table 4.3
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x

x

Table 5.2 hOCT2 substrate docking summarya.
Residue
MPP+ Cimetidine Epinephrine Metformin
Phe24
Asn157

x

x

Gln242

x

Tyr245

x

Thr246

x

Ser358
x

x
x

x

x

x

x

x

x

x

x

x

x

x

Glu387

x
x

x

x

Cys451

x
x

Cys474
Asp475

x

x

x

x

TPA
x

x

Gln363

Glu448

a

5-HT

x

Phe160

Tyr362

Quinine
x

x
x

Data acquired from Figure 3.7 and Table 3.3
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Table 5.3 hOCT3 substrate docking summarya.
Residue
MPP+ Epinephrine Metformin
5-HT
Phe36
x
x
Val40

x

x

Asn162

x

x

Met248

x

Trp358

x

x

Gln366
Glu451

x

a

x

x
x
x

Cys477
Asp478

x

x

Ser474
x
x

x

x

Data acquired from reference [164]
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TPA

x

It was previously reported that transport activity was completely abolished by an
Asp478 mutation in hOCT3 [164]. Through sequence alignment, the homologous site in
hOCT2 was identified as Asp475. The analogous conservative substitution of hOCT2
Asp475 was generated and stably expressed in CHO cells for functional screening
studies. In stark contrast to the hOCT3 results, the conserved mutant in hOCT2 showed
no difference from wild-type hOCT2 in transport activity of MPP + (data not shown). This
finding was supported by our hOCT2 in silico model wherein Asp475 was located outside
of the binding pocket and not predicted to interact with MPP +. The difference in transporter
function and affinity observed between hOCT3 Asp478Glu and hOCT2 Asp475Glu
suggests that the critical residues for MPP+-transporter interaction may vary depending
on the OCT paralog even for the same substrate and supports the contention that the
binding pocket in hOCT3 is distinct from that for hOCT1 and hOCT2. Despite a high
degree of sequence similarity (70%) and identity (51%) between hOCT2 and hOCT3, the
conserved aspartic acid residue (position 475 in hOCT2 and position 478 in hOCT3)
previously demonstrated to be essential for MPP+ interaction with hOCT3 appears to
exert no influence on MPP+ interaction with hOCT2.
The whole story detailing the most accurate depiction of the nature of the
physiochemical interactions for hOCT1, 2, and 3 is far from complete. The utilization of
homology models with the most closely related available transporter templates is currently
the leading strategy in achieving the overarching goal of the elucidation of the amino acids
critical for protein-ligand interaction. A comprehensive list of future work is necessary for
reaching stronger conclusions on the current hOCT interaction studies. This includes
additional studies to resolve the issue related to evaluating transporter targeting to plasma
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membrane. Acquiring this information will significantly dictate the validity of the claims
made for the hOCT non-functional mutants. Given the lack of specificity of commercial
antibodies tested and the inconclusive results of the GFP fusion construct studies, an
alternative approach could be the addition of a polypeptide tag with a known commercial
antibody (e.g. FLAG, c-Myc, 6x His) to the hOCT proteins. The establishment of double
mutants for hOCT1 and 2 will be helpful in providing additional valuable kinetic information
for functioning single mutants showing attenuated affinity. This analysis will in turn
determine any potential changes in double-mutant affinity for MPP + which could offer
further insight to the significance for specific residues involved with transporter-substrate
interaction. Finally, the additional amino acid residues that were identified in the analysis
of docking known structurally disparate hOCT substrates will need to be further
investigated. This can be conducted through the generation of stably transfect mutants
based on the additional residues identified and subsequent kinetic transport analysis of
the structurally disparate substrates.
The data collected from the current study in addition to the proposed future
experiments will bring forward new information regarding the substrate binding site of
hOCT1-3 of which will provide the necessary clues for their underlying mechanism of
transport. The identified amino acid residues that contribute to substrate binding may offer
useful insight to the transporter-substrate recognition by other members of the SLC22
family owing to their similarities in sequence homology. In the end, unveiling the critical
residues for hOCT1-3 will steer the future of drug design by improving safety/efficacy as
well as strengthening our predictions that eventually could lead to reductions in the rates
of harmful drug-drug interactions.
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